<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurogenetics</journal-id><journal-id journal-id-type="iso-abbrev">Neurogenetics</journal-id><journal-title-group><journal-title>Neurogenetics</journal-title></journal-title-group><issn pub-type="ppub">1364-6745</issn><issn pub-type="epub">1364-6753</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4573652</article-id><article-id pub-id-type="pmid">25980689</article-id><article-id pub-id-type="publisher-id">449</article-id><article-id pub-id-type="doi">10.1007/s10048-015-0449-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Splicing: is there an alternative contribution to Parkinson&#x02019;s disease?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>La Cognata</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Agata</surname><given-names>Velia</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Cavalcanti</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cavallaro</surname><given-names>Sebastiano</given-names></name><address><phone>+39 095 7436634</phone><email>sebastiano.cavallaro@cnr.it</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Institute of Neurological Sciences, Italian National Research Council, Via Paolo Gaifami 18, 95125 Catania, Sicily Italy </aff><aff id="Aff2"><label/>Institute of Neurological Sciences, Italian National Research Council, 87050 Piano Lago di Mangone, Cosenza, Calabria Italy </aff><aff id="Aff3"><label/>Department of Biomedical and Biotechnological Sciences, Section of Human Anatomy and Histology, University of Catania, Catania, Italy </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>16</volume><fpage>245</fpage><lpage>263</lpage><history><date date-type="received"><day>8</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>4</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Alternative splicing is a crucial mechanism of gene expression regulation that enormously increases the coding potential of our genome and represents an intermediate step between messenger RNA (mRNA) transcription and protein posttranslational modifications. Alternative splicing occupies a central position in the development and functions of the nervous system. Therefore, its deregulation frequently leads to several neurological human disorders. In the present review, we provide an updated overview on the impact of alternative splicing in Parkinson&#x02019;s disease (PD), the second most common neurodegenerative disorder worldwide. We will describe the alternative splicing of major PD-linked genes by collecting the current evidences about this intricate and not carefully explored aspect. Assessing the role of this mechanism on PD pathobiology may represent a central step toward an improved understanding of this complex disease.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Parkinson&#x02019;s disease</kwd><kwd>Alternative splicing</kwd><kwd>PD genes</kwd><kwd>mRNA splice transcripts</kwd><kwd>Protein isoforms</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>The flow of genetic information from DNA to RNA to protein has traditionally been considered the central dogma of molecular biology. Additional steps of regulation are currently well known, greatly expanding this simplistic framework and revealing the complex network that controls gene expression [<xref ref-type="bibr" rid="CR1">1</xref>]. One of these steps is represented by alternative splicing (AS), whereby a single gene gives rise to multiple messenger RNA (mRNA) transcripts and protein isoforms with different functional properties [<xref ref-type="bibr" rid="CR1">1</xref>]. It is estimated that 94&#x000a0;% of human protein-coding genes are alternatively spliced [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], and the main site of alternative splicing events is the central nervous system [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p>The alternative splicing process consists in the removal of the intronic regions from the RNA primary transcript and simultaneous assembly of the exonic regions in different combinations to form a mature mRNA, which is then polyadenilated, exported to the cytoplasm, and translated into protein. The accuracy and efficiency of pre-mRNA splicing process depend on a range of constitutive DNA sequence motifs: the donor and the acceptor splice sites, the lariat branch point, the polypyrimidine tract, and splicing enhancers and silencers (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, panel a). These motifs are recognized by a large macromolecular splicing machinery (called the spliceosome), which models the pre-mRNA while RNA polymerase II synthesizes it in the nucleus. The splicing machinery includes five spliceosomal uridine-rich small nuclear ribonucleoproteins (snRNPs) (U1, U2, U4, U5, and U6) and several non-snRNP protein splicing factors such as the serine/arginine (SR)-rich protein family and hnRNP proteins [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The splicing reaction relies on two transesterification steps that occur within the highly dynamic splicing machine. The stepwise molecular mechanisms of the splicing reaction are detailed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (panel a).<fig id="Fig1"><label>Fig. 1</label><caption><p>The alternative splicing mechanism. <bold>a</bold> Four main conserved DNA sequence motifs allow the splicing mechanism: the donor splice site GU (<italic>5</italic>&#x02032; <italic>SS</italic>), the acceptor splice site AG (<italic>3</italic>&#x02032; <italic>SS</italic>), the lariat branch point (<italic>A</italic>) located upstream of the acceptor site and the polypyrimidine tract (<italic>PPT</italic>) placed between the acceptor site and the branch point. The splicing machinery includes mainly five spliceosomal uridine-rich small nuclear ribonucleoproteins (snRNPs) (<italic>U1</italic>, <italic>U2</italic>, <italic>U4</italic>, <italic>U5</italic>, and <italic>U6</italic>) and further auxiliary RNA binding proteins. During the first step of spliceosome assembly, U1 snRNP base pairs with the 5&#x02032; splice site of the pre-mRNA (<italic>E complex</italic>), whereas U2 base pairs with the branch point (<italic>A complex</italic>). Then the tri-snRNP complex U4, U5, and U6 associates with the forming spliceosome (<italic>B complex</italic>), and both U1 and U4 are ejected. This allows U6 to replace U1 at the 5&#x02032; splice site (<italic>C complex</italic>) and leads to a U6&#x02013;U2 interaction that gets close together the 5&#x02032; splice site and the branch point, allowing for a transesterification step. At the end, U5 brings near the two exons, joining them through a second transesterification reaction. <bold>b</bold> Five major alternative splicing events are currently known: exon skipping/inclusion, use of alternative 3&#x02032; splice site, use of alternative 5&#x02032; splice site, mutually exclusive exons, and intron retention. In <italic>blue</italic>, are represented the constitutive exons. <italic>Yellow</italic> and <italic>red</italic> represent the alternatively spliced exons. The splicing events rely on the interplay between the constitutive splicing motifs, the splicing regulatory sequences, the RNA secondary structures, the components of the spliceosome, and further auxiliary RNA-binding proteins. However, how the spliceosome decides which exons to include remains currently not clear</p></caption><graphic xlink:href="10048_2015_449_Fig1_HTML" id="MO1"/></fig></p><p>Alternative splicing works as an on&#x02013;off switch in gene expression. It affects the expression levels, stability, half-life [via the nonsense-mediated mRNA decay (NMD)], and localization of the RNA messengers. It has also the potential to generate several protein isoforms with different biological properties, protein&#x02013;protein interactions, subcellular localization, signaling pathway, or catalytic ability. During the last years, great efforts have been made to decipher the intricate alternative splicing code. Five major alternative splicing events (i.e., cassette exons, use of alternative acceptor and/or donor sites, intron retention, and mutually exclusive exons) have been described up to now and are detailed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (panel b) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. However, how the spliceosome recognizes alternative exons and decides which exons to include remains not fully understood. Undoubtedly, there is more diversity in splice transcript variants than in protein isoforms. Although this is still not clear, different variants encode the same protein, but probably translate it with different efficiencies [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>The finely tuned splicing regulatory network can easily undergo alterations. An aberrant alternative splicing may arise from changes in regulatory sequences required for correct pre-mRNA processing (the so-called <italic>cis</italic>-acting mutations), as well as from mutations that affect components necessary for splicing regulation (<italic>trans</italic>-acting mutations). <italic>Cis</italic>- and <italic>trans</italic>-splicing aberrations represent direct causative agents of disease or more subtle contributions to the determinants of disease susceptibility or modulators of disease severity. An extensive range of neurological diseases has been already associated to both splicing defects, including Alzheimer&#x02019;s disease, retinitis pigmentosa, spinal muscular atrophy, muscular dystrophy, neurofibromatosis, and fragile X-associated tremor/ataxia syndrome [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. In this broad neurological disorder scenario, the relevance of alternative splicing in Parkinson&#x02019;s disease&#x000a0;(PD) is not still clear, and the splicing mechanisms that regulate PD-related genes remain mostly unknown.</p><p>Here, we provide an updated overview of the current knowledge about the impact of alternative splicing on Parkinson&#x02019;s disease. Firstly, we will take into account the most common PD-related genes &#x0201c;one by one&#x0201d; by analyzing their alternative transcripts currently known and their involvement in this disease. Then, we will describe the few studies that have globally analyzed the changes of splice variant expression in PD patients through genome-wide RNA expression approaches. Finally, we will briefly describe the current evidences about the alternative splicing modulation in PD through noncoding RNAs [microRNA (miRNA) and long noncoding RNA (lcnRNA)].</p></sec><sec id="Sec2"><title>Genetics of Parkinson&#x02019;s disease</title><p>PD is the second most common neurodegenerative disorder worldwide, characterized by resting tremor, bradykinesia, stiffness of movement, and postural instability. These symptoms are derived from the progressive loss of neurons from the <italic>substantia nigra pars compacta</italic>, coupled with an accumulation of intraneuronal aggregates called Lewy bodies.</p><p>Despite significant progresses in the understanding of PD pathogenesis, the exact etiology of PD remains unknown. Over the past 15&#x000a0;years, an even more detailed knowledge of the genetic factors that contribute to PD has emerged through different research strategies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Linkage mapping analysis, genome-wide association studies (GWAS), and next-generation sequencing technologies are revealing an increasing number of locus and genes strongly linked to either autosomal dominant (<italic>SNCA</italic>-<italic>PARK1</italic>, <italic>LRRK2</italic>-<italic>PARK8</italic>, <italic>VPS35</italic>-<italic>PARK17</italic>, and <italic>GBA</italic>), or typical recessive (<italic>PARKIN</italic>-<italic>PARK2</italic>, <italic>PINK1</italic>-<italic>PARK6</italic>, and <italic>DJ1</italic>-<italic>PARK7</italic>) and atypical recessive (<italic>ATP13A2</italic>-<italic>PARK9</italic>, <italic>PLA2G6</italic>-<italic>PARK14</italic>, and <italic>FBXO7</italic>-<italic>PARK15</italic>) or X-linked (<italic>ATP6A2</italic> and <italic>TAF1</italic>) forms of disease. For the sake of completeness, we mention here further monogenic loci, not confirmed genes, or risk factor genes (i.e., <italic>PARK3</italic>, <italic>UCHL1</italic>, <italic>PARK10</italic>, <italic>GIGYF2</italic>, <italic>PARK12</italic>, <italic>HTRA2</italic>, <italic>PARK16</italic>, <italic>EIF4G1</italic>, <italic>DNAJ</italic>, <italic>HLA</italic>-<italic>DR</italic>, <italic>GAK</italic>-<italic>DGKQ</italic>, <italic>SYNJ1</italic>, and <italic>GBAP1</italic>) [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, a large-scale meta-analysis of genome-wide association data is revealing a wide range of additional loci having genome-wide significant association [<xref ref-type="bibr" rid="CR18">18</xref>]. However, we will overlook their discussion because of the few data in the literature regarding their splicing regulation in pathological conditions.</p><p>In the next paragraphs, we will describe the alternative spliced mRNA variants of PD genes and the current scientific data demonstrating their involvement in PD pathogenesis. For a more complete picture, we have also added some further implicated genes (<italic>SRRM2</italic>, <italic>MAO</italic>-<italic>B</italic>, <italic>SNCAIP</italic>, <italic>MAPT</italic>, and <italic>GBA</italic>), indicated as other PD-related genes, which are not directly causative genes, but whose splicing regulation seems to be altered in PD states.</p><sec id="Sec3"><title>Autosomal dominant PD genes</title><sec id="Sec4"><title>SNCA</title><p>Alpha-synuclein, encoded by <italic>SNCA</italic> gene, is a small, natively unfolded presynaptic protein linked to PD [<xref ref-type="bibr" rid="CR19">19</xref>]. Aggregates of alpha-synuclein protein represent the neuropathological hallmark lesions of PD and constitute the major components of Lewy bodies. Genetically, mutations in <italic>SNCA</italic> gene were the first to be associated with PD family inheritance. Missense mutations in coding regions (Ala53Thr, Ala30Pro, and Glu46Lys), single nucleotide substitution in 3&#x02032; untranslated region (3&#x02032; UTR), and dose-dependent genomic multiplications (duplications or triplications) of the gene cause both monogenic and sporadic forms of PD [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Some point mutations in splice donor sites have also been reported (IVS2&#x02009;+&#x02009;9A&#x02009;&#x0003e;&#x02009;C) [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p><italic>SNCA</italic> gene maps to chromosome 4q22.1 and contains six exons spanning about 114&#x000a0;kb [<xref ref-type="bibr" rid="CR21">21</xref>]. The set of mRNAs produced by <italic>SNCA</italic> gene includes the <italic>full</italic>-<italic>length</italic> transcript, commonly known as SNCA-140 from the amino acidic length of the encoded protein, and corresponds to SNCA-001, SNCA-002, SNCA-003, SNCA-006, and SNCA-008 mRNAs from Ensembl library (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Further additional splicing variants, known as SNCA-126, SNCA-112, and SNCA-98 and corresponding to (i) SNCA-004, SNCA-203, SNCA-201, (ii) SNCA-005, SNCA-202, and (iii) SNCA-010, respectively, are generated by in-frame excision of exons 3, 5, or both (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Two additional splice variants (SNCA-009 and SNCA-007) are generated from an inner transcription start and encode proteins of 115 and 97 amino acids, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). SNCA-140, SNCA-126, and SNCA-112 are expressed in a broad spectrum of human tissues, while SNCA-98 seems to be a brain-specific splice variant with varying expression levels in different areas of fetal and adult brain [<xref ref-type="bibr" rid="CR23">23</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Alternative splice variants of human autosomal dominant PD genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene name</th><th>Transcript number</th><th>Ensembl name</th><th>Genbank accession number</th><th>Protein length</th></tr></thead><tbody><tr><td rowspan="13">
<italic>SNCA</italic>
</td><td align="left">1.</td><td>SNCA-003</td><td>NM_001146055</td><td align="left">140 aa</td></tr><tr><td align="left">2.</td><td>SNCA-202</td><td>NM_007308</td><td align="left">112 aa</td></tr><tr><td align="left">3.</td><td>SNCA-203</td><td>&#x02013;</td><td align="left">126 aa</td></tr><tr><td align="left">4.</td><td>SNCA-201</td><td>&#x02013;</td><td align="left">126 aa</td></tr><tr><td align="left">5.</td><td>SNCA-005</td><td>&#x02013;</td><td align="left">112 aa</td></tr><tr><td align="left">6.</td><td>SNCA-001</td><td>NM_001146054</td><td align="left">140 aa</td></tr><tr><td align="left">7.</td><td>SNCA-002</td><td>NM_000345</td><td align="left">140 aa</td></tr><tr><td align="left">8.</td><td>SNCA-008</td><td>&#x02013;</td><td align="left">140 aa</td></tr><tr><td align="left">9.</td><td>SNCA-006</td><td>&#x02013;</td><td align="left">140 aa</td></tr><tr><td align="left">10.</td><td>SNCA-004</td><td>&#x02013;</td><td align="left">126 aa</td></tr><tr><td align="left">11.</td><td>SNCA-010</td><td>&#x02013;</td><td align="left">98 aa</td></tr><tr><td align="left">12.</td><td>SNCA-009</td><td>&#x02013;</td><td align="left">115 aa</td></tr><tr><td align="left">13.</td><td>SNCA-007</td><td>&#x02013;</td><td align="left">67 aa</td></tr><tr><td rowspan="7">
<italic>LRRK2</italic>
</td><td align="left">1.</td><td>LRRK2-002</td><td>&#x02013;</td><td align="left">1271 aa</td></tr><tr><td align="left">2.</td><td>LRRK2-004</td><td>NM_198578</td><td align="left">2527 aa</td></tr><tr><td align="left">3.</td><td>LRRK2-005</td><td>&#x02013;</td><td align="left">207 aa</td></tr><tr><td align="left">4.</td><td>LRRK2-001</td><td>&#x02013;</td><td align="left">521 aa</td></tr><tr><td align="left">5.</td><td>LRRK2-003</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">6.</td><td>LRRK2-006</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">7.</td><td>LRRK2-007</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="11">
<italic>VPS35</italic>
</td><td align="left">1.</td><td>VPS35-001</td><td>NM_018206</td><td align="left">796 aa</td></tr><tr><td align="left">2.</td><td>VPS35-002</td><td>&#x02013;</td><td align="left">48 aa</td></tr><tr><td align="left">3.</td><td>VPS35-011</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">4.</td><td>VPS35-012</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">5.</td><td>VPS35-006</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">6.</td><td>VPS35-003</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">7.</td><td>VPS35-010</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">8.</td><td>VPS35-005</td><td>&#x02013;</td><td align="left">47 aa</td></tr><tr><td align="left">9.</td><td>VPS35-008</td><td>&#x02013;</td><td align="left">41 aa</td></tr><tr><td align="left">10.</td><td>VPS35-007</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">11.</td><td>VPS35-004</td><td>&#x02013;</td><td>No protein</td></tr></tbody></table><table-wrap-foot><p>Gene name, Ensembl transcript names, GenBank accession numbers, and relative encoded amino acidic protein length of splice variants are reported in the table. Number in the column &#x0201c;Transcript number&#x0201d; identifies the transcript in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>
</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Structures of the alternative splicing variants of human dominant PD genes. Structures of the described mRNA splicing variants are represented in the figure as reported in Ensembl library (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/index.html">http://www.ensembl.org/index.html</ext-link>). On the <italic>left</italic>, each variant is indicated with a number corresponding to that indicated in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. <italic>LRRK2</italic> gene is illustrated in 5&#x02032;-3&#x02032; sense, while <italic>SNCA</italic> and <italic>VPS35</italic> genes are illustrated in antisense corresponding to their 3&#x02032;-5&#x02032; sense transcription</p></caption><graphic xlink:href="10048_2015_449_Fig2_HTML" id="MO2"/></fig></p><p>The expression profile of SNCA-140, SNCA-126, SNCA-112, and SNCA-98 splice variants is different in the various brain areas under normal and pathological states. Compared to healthy controls, in PD <italic>frontal cortex</italic>, all these four transcripts are overexpressed, with significant upregulation of SNCA-126 [<xref ref-type="bibr" rid="CR24">24</xref>]. In PD <italic>substantia nigra</italic>, only the three shorter transcripts have been observed significantly overexpressed [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], while higher SNCA-112 and SNCA-98 levels are also present in the <italic>cerebellum</italic> [<xref ref-type="bibr" rid="CR25">25</xref>]. Different expression profiles of <italic>SNCA</italic> variants also occur in other forms of neurodegenerative disorders. Both SNCA-140 and SNCA-126 downregulation and SNCA-98 overexpression have been reported in dementia with Lewy bodies and Alzheimer&#x02019;s disease, while SNCA-112 is upregulated in dementia with Lewy bodies and downregulated in Alzheimer&#x02019;s disease [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p>Some interesting data emerge on SNCA-112 variant. An association between PD risk-associated single nucleotide polymorphisms (SNPs) within the 3&#x02032; region of <italic>SNCA</italic> gene and higher SNCA-112 ratio level has been observed in about 100 of frontal cortex samples. These data reveal the <italic>cis</italic>-regulatory effect of these mutations on splicing mechanism [<xref ref-type="bibr" rid="CR29">29</xref>]. The expression of SNCA-112 is also abundantly induced by some parkinsonism mimetics (MPP+, rotenone) and related oxidants [<xref ref-type="bibr" rid="CR30">30</xref>]. However, the reason for these effects remains unclear.</p><p>In addition to splice variants, specific RNA transcript isoforms of <italic>SNCA</italic> with an extended 3&#x02032; untranslated region have been described and appear selectively linked to pathological processes [<xref ref-type="bibr" rid="CR31">31</xref>]. However, this review is focusing only on the mRNA splice variants; thus, their discussion will be omitted.</p><p>The 140 amino acid isoform is a small protein with a molecular weight of 14.5&#x000a0;kDa. It is composed of three distinct regions: (1) an amino terminus containing amphipathic helices conferring the propensity to bind membranes; (2) a central hydrophobic region, the so-called non-Ab component (NAC), which confers the b-sheet potential; and (3) an acid glutamatergic carboxyl terminus that is highly negatively charged and prone to be unstructured [<xref ref-type="bibr" rid="CR19">19</xref>]. Structural changes in the shorter splicing isoforms can be predicted as a result of exon skipping events. SNCA-126-predicted isoform shows interruption of the N-terminal protein&#x02013;membrane interaction domain [<xref ref-type="bibr" rid="CR32">32</xref>]; SNCA-112 is significantly shorter in the unstructured C-terminal [<xref ref-type="bibr" rid="CR32">32</xref>], while SNCA-98 isoform results in a truncated protein consisting almost only of the central region containing NAC [<xref ref-type="bibr" rid="CR23">23</xref>]. Recently, a lower aggregation propensity of the shorter isoforms has been demonstrated in vitro [<xref ref-type="bibr" rid="CR33">33</xref>]. In addition, morphology studies by using electron microscopy have shown straight fibrils for SNCA-140, shorter fibrils mostly arranged in parallel arrays for SNCA-126, and circular structures for SNCA-98 [<xref ref-type="bibr" rid="CR33">33</xref>]. These data open new insights regarding the formation of Lewy bodies induced by alpha-synuclein.</p><p>Numerous functions of alpha-synuclein have been proposed, counting molecular chaperone, regulator of dopamine uptake and homeostasis, inhibitor of phospholipase D2, downregulator of p53 pathway [<xref ref-type="bibr" rid="CR32">32</xref>], and promoter of the SNARE-complex assembling [<xref ref-type="bibr" rid="CR34">34</xref>]. Unfortunately, nothing is known about the specific pathophysiological roles of each alpha-synuclein isoform and their relative posttranslational modifications (i.e., phosphorylations, nitration, sumoylation, oxidation, glycosylation, cleavage, and ubiquitination), which are known to play a key role in SNCA functions and regulation [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec5"><title>LRRK2</title><p><italic>LRRK2</italic> encodes for leucine-rich repeat kinase 2 (or dardarin), which is a large 2527 amino acid multidomain protein. The protein consists of multiple conserved well-defined domains including a small GTPase-like domain (Ras of complex proteins or ROC), a domain of unknown function termed the C-terminal of ROC (COR), a kinase domain, as well as several protein interaction domains [e.g., the leucine-rich repeat (LRR), the WD40 domain, the ankyrin repeat domain, and the armadillo repeat region]. The precise physiological function of LRRK2 is unknown. However, LRRK2 seems implicated in different cellular functions as neurite outgrowth, cytoskeletal maintenance, vesicle trafficking, and autophagic protein degradation [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>The <italic>LRRK2</italic> gene spans a genomic region of 144&#x000a0;kb, with 51 exons, and harbors the most common mutations linked to both autosomal dominant inherited late-onset and sporadic PD. The missense mutations known so far are spread over the whole <italic>LRRK2</italic> gene and affect all functional domains. Some mutations have much higher frequencies than others, such as Gly2019Ser and mutations altering codon Arg1441, respectively, in the kinase and ROC domains. In addition, several unclear pathogenic mutations affecting splice sites have been observed (IVS19&#x02009;+&#x02009;5_8delGTAA, IVS25-8delT, IVS27-9C&#x02009;&#x0003e;&#x02009;T, IVS30-6C&#x02009;&#x0003e;&#x02009;T, IVS31&#x02009;+&#x02009;3A&#x02009;&#x0003e;&#x02009;G, IVS32&#x02009;+&#x02009;14G&#x02009;&#x0003e;&#x02009;A, IVS33&#x02009;+&#x02009;6&#x000a0;T&#x02009;&#x0003e;&#x02009;A, IVS37-9A&#x02009;&#x0003e;&#x02009;G, IVS38&#x02009;+&#x02009;7C&#x02009;&#x0003e;&#x02009;T, IVS46-14&#x000a0;T&#x02009;&#x0003e;&#x02009;A, and IVS46-8delT) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>In addition to the full-length transcript (LRRK2-004), further <italic>LRRK2</italic> shorter transcripts are deposited in Ensembl library (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Despite the existence of these transcripts, there are currently no data analyzing the splicing profile of this gene in PD states. Recently, a gene expression and splicing analysis of the <italic>LRRK2</italic> locus have been carried on [<xref ref-type="bibr" rid="CR44">44</xref>]. Both exon array and RT-PCR methods confirm the existence of an isoform with spliced out exons 32&#x02013;33 in the <italic>substantia nigra</italic> and an isoform with exon 32 alone spliced out in the <italic>occipital cortex</italic>, <italic>medulla</italic>, and <italic>cerebellum</italic> of healthy humans [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>Further evidences on <italic>LRRK2</italic> splicing have been observed by Giesert and collaborators [<xref ref-type="bibr" rid="CR45">45</xref>], who have conducted a study in various brain regions and organs from adult mice. In this regard, it should be considered that <italic>LRRK2</italic> is highly conserved in human and mouse and that several transgenic animal models have been created. Giesert et al. [<xref ref-type="bibr" rid="CR45">45</xref>] have identified two <italic>LRRK2</italic> splice variants: one with skipped exon 5, primarily expressed in astrocytes, and another truncated variant terminating with an alternative exon 42a barely detectable in the microglia but highly expressed in neurons and astrocytes. Protein-structure predictions reveal that the loss of exon 5 may generate a smaller protein with changed affinity of binding partners, while the alternative exon 42a may lead to changes of its enzymatic activity. In addition, the protein-interaction domain WD40 would also be absent in such truncation. Interestingly, the deletion of this domain in the Zebrafish LRRK2 ortholog (zLRRK2) causes parkinsonism-like phenotype including loss of dopaminergic neurons in diencephalon and locomotion defects [<xref ref-type="bibr" rid="CR46">46</xref>]. Further studies will need to assess the involvement of <italic>LRRK2</italic> alternative splice variants in PD.</p></sec><sec id="Sec6"><title>VPS35</title><p>In 2011, two groups reported the identification of the same missense mutation (p.Asp620Asn) in the vacuolar protein sorting 35 (<italic>VPS35</italic>) gene as a novel cause of autosomal dominant PD [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. <italic>VPS35</italic> was the first PD gene found by a direct whole exome sequencing in large families of Austrian and Swiss origins. An in-depth sequence analyses of all coding, noncoding, and exon&#x02013;intron boundaries <italic>VPS35</italic> genetic regions have been performed in a large well-characterized cohort of Lewy body disorders, including PD patients, PD with dementia, and dementia with Lewy bodies [<xref ref-type="bibr" rid="CR49">49</xref>]. In addition to three novel missense mutations, silent and intronic variations, predicted to activate cryptic splice sites, have been observed in the patient&#x02019;s group but not in controls. However, the pathogenicity of these mutations was not completely conclusive since these mutations were not supported by segregation analysis in family relatives [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p>Various spliced transcript variants of this gene are reported in Ensembl library (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), but the majority of them are processed for degradation and do not encode proteins.</p></sec></sec><sec id="Sec7"><title>Autosomal recessive PD genes</title><sec id="Sec8"><title>Early-onset typical PD genes</title><sec id="FPar1"><title><italic>PARK2</italic></title><p>Mutations in <italic>PARK2</italic> gene (also known as <italic>PARK2 parkin RBR E3 ubiquitin</italic>-<italic>protein ligase</italic>) are the most common cause (50&#x000a0;% of cases) of autosomal recessive juvenile parkinsonism (AR-JP), a form of early-onset parkinsonism characterized by good and prolonged response to levodopa and a benign, slow course. <italic>PARK2</italic> mutations also explain ~15&#x000a0;% of the sporadic cases with onset before 45 [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] and act as susceptibility alleles for late-onset forms of Parkinson&#x02019;s disease (2&#x000a0;% of cases) [<xref ref-type="bibr" rid="CR52">52</xref>]. Along with about 200 mutations currently identified in <italic>PARK2</italic> coding region, several point mutations in splice acceptor or donor sites (introns 1, 6, 7, 10, 12, 13, and 16) have been identified in PD patients [<xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>].</p><p><italic>PARK2</italic> gene spans more than 1.38&#x000a0;Mb of genomic DNA in the long arm of chromosome 6 (6q25.2&#x02013;q27) and contains 12 exons, which are alternatively spliced to produce at least 11 different splicing variants (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR59">59</xref>]. The full-length <italic>PARK2</italic> transcript (PARK2-004) encodes a protein of 465 amino acids (parkin) [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR59">59</xref>] acting in numerous molecular pathways (protein turnover, stress response, mitochondrial homeostasis, mitophagy, mitochondrial DNA stability, metabolism, cell growth, and survival) [<xref ref-type="bibr" rid="CR62">62</xref>]. Multiple parkin isoforms likely arising from <italic>PARK2</italic> splicing variants have been observed in different brain areas through Western blot studies [<xref ref-type="bibr" rid="CR9">9</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Alternative splice variants of human autosomal recessive PD genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene name</th><th>Transcript number</th><th>Ensembl name</th><th>Genbank accession number</th><th>Protein length</th></tr></thead><tbody><tr><td rowspan="11">
<italic>PARK2</italic>
</td><td align="left">1.</td><td>PARK2-004</td><td>NM_004562</td><td align="left">465 aa</td></tr><tr><td align="left">2.</td><td>PARK2-005</td><td>NM_013987</td><td align="left">437 aa</td></tr><tr><td align="left">3.</td><td>PARK2-006</td><td>NM_013988</td><td align="left">316 aa</td></tr><tr><td align="left">4.</td><td>PARK2-001</td><td>&#x02013;</td><td align="left">274 aa</td></tr><tr><td align="left">5.</td><td>PARK2-003</td><td>&#x02013;</td><td align="left">274 aa</td></tr><tr><td align="left">6.</td><td>PARK2-007</td><td>&#x02013;</td><td align="left">218 aa</td></tr><tr><td align="left">7.</td><td>PARK2-201</td><td>&#x02013;</td><td align="left">176 aa</td></tr><tr><td align="left">8.</td><td>PARK2-204</td><td>&#x02013;</td><td align="left">87 aa</td></tr><tr><td align="left">9.</td><td>PARK2-002</td><td>&#x02013;</td><td align="left">368 aa</td></tr><tr><td align="left">10.</td><td>PARK2-202</td><td>&#x02013;</td><td align="left">74 aa</td></tr><tr><td align="left">11.</td><td>PARK2-203</td><td>&#x02013;</td><td align="left">201 aa</td></tr><tr><td rowspan="3">
<italic>PINK1</italic>
</td><td align="left">1.</td><td>PINK1-001</td><td>NM_032409</td><td align="left">581 aa</td></tr><tr><td align="left">2.</td><td>PINK1-002</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">3.</td><td>PINK1-003</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="10">
<italic>DJ1</italic>
</td><td align="left">1.</td><td>PARK7-004</td><td>&#x02013;</td><td align="left">189 aa</td></tr><tr><td align="left">2.</td><td>PARK7-002</td><td>NM_001123377; NM_007262</td><td align="left">189 aa</td></tr><tr><td align="left">3.</td><td>PARK7-007</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">4.</td><td>PARK7-001</td><td>&#x02013;</td><td align="left">189 aa</td></tr><tr><td align="left">5.</td><td>PARK7-003</td><td>&#x02013;</td><td align="left">169 aa</td></tr><tr><td align="left">6.</td><td>PARK7-008</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">7.</td><td>PARK7-005</td><td>&#x02013;</td><td align="left">189 aa</td></tr><tr><td align="left">8.</td><td>PARK7-006</td><td>&#x02013;</td><td align="left">189 aa</td></tr><tr><td align="left">9.</td><td>PARK7-009</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">10.</td><td>PARK7-010</td><td>&#x02013;</td><td align="left">160 aa</td></tr><tr><td rowspan="15">
<italic>ATP13A2</italic>
</td><td align="left">1.</td><td>ATP13A2-001</td><td>NM_022089</td><td align="left">1180 aa</td></tr><tr><td align="left">2.</td><td>ATP13A2-002</td><td>NM_001141974</td><td align="left">1158 aa</td></tr><tr><td align="left">3.</td><td>ATP13A2-005</td><td>NM_001141973</td><td align="left">1175 aa</td></tr><tr><td align="left">4.</td><td>ATP13A2-004</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">5.</td><td>ATP13A2-003</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">6.</td><td>ATP13A2-010</td><td>&#x02013;</td><td align="left">191 aa</td></tr><tr><td align="left">7.</td><td>ATP13A2-007</td><td>&#x02013;</td><td align="left">398 aa</td></tr><tr><td align="left">8.</td><td>ATP13A2-014</td><td>&#x02013;</td><td align="left">258 aa</td></tr><tr><td align="left">9.</td><td>ATP13A2-009</td><td>&#x02013;</td><td align="left">321 aa</td></tr><tr><td align="left">10.</td><td>ATP13A2-006</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">11.</td><td>ATP13A2-201</td><td>&#x02013;</td><td align="left">228 aa</td></tr><tr><td align="left">12.</td><td>ATP13A2-013</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">13.</td><td>ATP13A2-011</td><td>&#x02013;</td><td align="left">190 aa</td></tr><tr><td align="left">14.</td><td>ATP13A2-012</td><td>&#x02013;</td><td align="left">191 aa</td></tr><tr><td align="left">15.</td><td>ATP13A2-008</td><td>&#x02013;</td><td align="left">188 aa</td></tr><tr><td rowspan="28">
<italic>PLA2G6</italic>
</td><td align="left">1.</td><td>PLA2G6-001</td><td>NM_003560</td><td align="left">806 aa</td></tr><tr><td align="left">2.</td><td>PLA2G6-201</td><td>NM_001004426</td><td align="left">752 aa</td></tr><tr><td align="left">3.</td><td>PLA2G6-002</td><td>NM_001199562</td><td align="left">752 aa</td></tr><tr><td align="left">4.</td><td>PLA2G6-025</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">5.</td><td>PLA2G6-021</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">6.</td><td>PLA2G6-014</td><td>&#x02013;</td><td align="left">166 aa</td></tr><tr><td align="left">7.</td><td>PLA2G6-024</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">8.</td><td>PLA2G6-013</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">9.</td><td>PLA2G6-026</td><td>&#x02013;</td><td align="left">168 aa</td></tr><tr><td align="left">10.</td><td>PLA2G6-015</td><td>&#x02013;</td><td align="left">120 aa</td></tr><tr><td align="left">11.</td><td>PLA2G6-010</td><td>&#x02013;</td><td align="left">99 aa</td></tr><tr><td align="left">12.</td><td>PLA2G6-023</td><td>&#x02013;</td><td align="left">226 aa</td></tr><tr><td align="left">13.</td><td>PLA2G6-009</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">14.</td><td>PLA2G6-027</td><td>&#x02013;</td><td align="left">51 aa</td></tr><tr><td align="left">15.</td><td>PLA2G6-022</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">16.</td><td>PLA2G6-012</td><td>&#x02013;</td><td align="left">151 aa</td></tr><tr><td align="left">17.</td><td>PLA2G6-019</td><td>&#x02013;</td><td align="left">124 aa</td></tr><tr><td align="left">18.</td><td>PLA2G6-011</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">19.</td><td>PLA2G6-020</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">20.</td><td>PLA2G6-008</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">21.</td><td>PLA2G6-016</td><td>&#x02013;</td><td align="left">229 aa</td></tr><tr><td align="left">22.</td><td>PLA2G6-005</td><td>&#x02013;</td><td align="left">99 aa</td></tr><tr><td align="left">23.</td><td>PLA2G6-018</td><td>&#x02013;</td><td align="left">157 aa</td></tr><tr><td align="left">24.</td><td>PLA2G6-003</td><td>&#x02013;</td><td align="left">99 aa</td></tr><tr><td align="left">25.</td><td>PLA2G6-017</td><td>&#x02013;</td><td align="left">197 aa</td></tr><tr><td align="left">26.</td><td>PLA2G6-007</td><td>&#x02013;</td><td align="left">80 aa</td></tr><tr><td align="left">27.</td><td>PLA2G6-004</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">28.</td><td>PLA2G6-006</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="9">
<italic>FBXO7</italic>
</td><td align="left">1.</td><td>FBXO7-003</td><td>&#x02013;</td><td align="left">41 aa</td></tr><tr><td align="left">2.</td><td>FBXO7-001</td><td>NM_012179</td><td align="left">522 aa</td></tr><tr><td align="left">3.</td><td>FBXO7-004</td><td>&#x02013;</td><td align="left">49 aa</td></tr><tr><td align="left">4.</td><td>FBXO7-005</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">5.</td><td>FBXO7-006</td><td>&#x02013;</td><td align="left">129 aa</td></tr><tr><td align="left">6.</td><td>FBXO7-002</td><td>NM_001033024; NM_001257990</td><td align="left">408 aa</td></tr><tr><td align="left">7.</td><td>FBXO7-007</td><td>&#x02013;</td><td align="left">54 aa</td></tr><tr><td align="left">8.</td><td>FBXO7-008</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">9.</td><td>FBXO7-010</td><td>&#x02013;</td><td>No protein</td></tr></tbody></table><table-wrap-foot><p>Gene name, Ensembl transcript names, GenBank accession numbers, and relative encoded amino acidic protein length of splice variants are reported in the table. Number in the column &#x0201c;Transcript number&#x0201d; identifies the transcript in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>
</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Structures of the alternative splicing variants of human recessive PD genes. Structures of the described mRNA splicing variants are represented in the figure as reported in Ensembl library (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/index.html">http://www.ensembl.org/index.html</ext-link>). On the <italic>left</italic>, each variant is indicated with a <italic>number</italic> corresponding to that indicated in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. All transcripts are illustrated in 5&#x02032;-3&#x02032; sense, except <italic>PARK2</italic>, <italic>ATP13A2</italic>, and <italic>PLA2G6</italic> genes, which are illustrated in antisense corresponding to their 3&#x02032;&#x02013;5&#x02032; sense transcription</p></caption><graphic xlink:href="10048_2015_449_Fig3_HTML" id="MO3"/></fig></p><p>The extensive alternative splicing of <italic>PARK2</italic> is differently regulated both at transcript and protein level in tissues and cells [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. Distinct expression patterns of <italic>PARK2</italic> splice variants emerge in human brain regions [<xref ref-type="bibr" rid="CR69">69</xref>] and leukocytes [<xref ref-type="bibr" rid="CR68">68</xref>], in rat brain, in neuronal and glial cells [<xref ref-type="bibr" rid="CR67">67</xref>], and in a wide variety of mouse tissues (brain, heart, lung, liver, skeletal muscle, kidney, and testis) [<xref ref-type="bibr" rid="CR64">64</xref>]. At the protein level, <italic>PARK2</italic> protein isoforms show a differential distribution in human leukocytes [<xref ref-type="bibr" rid="CR70">70</xref>] and aged brain [<xref ref-type="bibr" rid="CR71">71</xref>], as well as in different rat and mouse nervous system areas (cerebral cortex/diencephalons, hippocampus, cerebellum, brainstem, striatum, spinal cord, and <italic>substantia nigra</italic>), peripheral tissues (heart, liver, spleen, pancreas, and kidney), and developmental stages [<xref ref-type="bibr" rid="CR72">72</xref>&#x02013;<xref ref-type="bibr" rid="CR76">76</xref>].</p><p>Emerging evidences support the importance of <italic>PARK2</italic> splice variant expression changes in disease development. Differential expression of <italic>PARK2</italic> transcripts have been identified in the frontal cortex of Parkinson&#x02019;s disease, pure dementia with Lewy bodies, common Lewy body disease, and Alzheimer&#x02019;s disease patients, compared to controls [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Particularly, two <italic>PARK2</italic> splicing variants are significantly overexpressed in PD [<xref ref-type="bibr" rid="CR65">65</xref>]. Another study reports both an increase in the expression level of a parkin splice variant and a decrease of the wild type between PD patients and healthy controls [<xref ref-type="bibr" rid="CR66">66</xref>]. The differential and disease-specific expression profiles of <italic>PARK2</italic> alternative splice variants suggest a role for splicing deregulation in the development of neurodegenerative disorders.</p></sec><sec id="FPar2"><title>PINK1</title><p>Homozygous or compound heterozygous loss-of-function mutations in <italic>PTEN</italic>-<italic>induced putative kinase 1</italic> (<italic>PINK1</italic>) are the second most frequent cause of autosomal recessive early-onset parkinsonism. Mutation frequency varies geographically from 1 to 9&#x000a0;% depending on ethnic background [<xref ref-type="bibr" rid="CR77">77</xref>]. The <italic>PINK1</italic> mutation spectrum involves nonsense and missense mutations, insertions, or deletions, and whole gene or single/multiple exon copy number variants located across the entire gene [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p><italic>PINK1</italic> gene maps in the short arm of chromosome 1 (1p36.12), encompassing ~18&#x000a0;kb of genomic DNA. Its coding sequence is spread over eight exons. In addition to the full length (PINK1-001), two shorter variants exist but do not produce proteins (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p>Some interesting findings emerge regarding the splicing regulation of exon 7. A 23-bp deletion disrupting the splice acceptor site of exon 7 has been detected in a sporadic parkinsonian patient, producing several aberrant mRNAs [<xref ref-type="bibr" rid="CR79">79</xref>]. Moreover, whole exon 7 deletion and a novel U1-dependent 5&#x02032; splice-site mutation in exon 7 have been found in a large Spanish family with PD members [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p>The PINK1 protein is a putative serine/threonine kinase of 581 amino acids involved in mitochondrial response to cellular and oxidative stress [<xref ref-type="bibr" rid="CR81">81</xref>]. It has been demonstrated that at least two isoforms are expressed in the human brain: a full-length protein of ~63&#x000a0;kDa and an N-terminally truncated isoform of 52&#x000a0;kDa [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>]. An additional isoform of approximately 45&#x000a0;kDa has been suggested, although it has not been extensively studied [<xref ref-type="bibr" rid="CR85">85</xref>]. The 52-kDa isoform seems to originate by enzymatic cleavage of PARL [<xref ref-type="bibr" rid="CR86">86</xref>]; however, the exact nature of the isoforms, the precise reason for the cleavage, and the functional roles of these three different isoforms require further studies.</p></sec><sec id="FPar3"><title>DJ1</title><p>Mutations in the <italic>DJ1</italic> (also known as <italic>PARK7</italic>) gene are the less common cause of autosomal recessive parkinsonism (~1&#x000a0;% of early-onset PD) [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. A large homozygous deletion and a missense mutation (L166P) in <italic>DJ</italic>-<italic>1</italic> gene were first identified in both Italian and Dutch consanguineous families [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Additional mutations have been collected in other PD families and include missense mutations in coding and promoter regions, frame shifts, copy number variations [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR88">88</xref>], and splice site alterations [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>].</p><p><italic>DJ</italic>-<italic>1</italic> gene maps to chromosome 1 (1p36.23) and includes seven exons. Several spliced transcript variants have been identified encoding the same protein (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Two shorter transcripts (the first lacking exon 4 and the second starting in an inner transcription point) encode for smaller proteins (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p>The product of <italic>DJ</italic>-<italic>1</italic> gene is a highly conserved protein of 189 amino acids belonging to the peptidase C56 family [<xref ref-type="bibr" rid="CR94">94</xref>]. It is a multifunctional protein, acting as a positive regulator of transcription, redox-sensitive chaperone, sensor for oxidative stress, and apparently protects neurons from ROS-induced apoptosis [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. In the human brain and peripheral blood, several <italic>DJ</italic>-<italic>1</italic> isoforms exist and differ on their isoelectric point (p<italic>I</italic>) [<xref ref-type="bibr" rid="CR97">97</xref>&#x02013;<xref ref-type="bibr" rid="CR100">100</xref>]. The relative abundance of these different <italic>DJ</italic>-<italic>1</italic> isoforms appears to be altered in PD, and therefore, blood <italic>DJ</italic>-<italic>1</italic> isoforms have been proposed as potential biomarkers for Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR101">101</xref>]. The different pI of each variant are believed to result from posttranslational modifications that alter the intrinsic charge of the protein [<xref ref-type="bibr" rid="CR101">101</xref>]. Interestingly, it has been demonstrated that one of the major binding partners of DJ-1 in dopaminergic neuronal cells is the splicing factor proline/glutamine-rich (SFPQ protein) [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. SFPQ, originally identified as a polypyrimidine tract-binding protein, is part of the spliceosome C complex and is required for in vitro splicing of pre-mRNA [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. DJ-1 binding to SFPQ modulates its transcriptional activity and, therefore, tunes its effect on splicing regulation. DJ-1 mutations could reverberate on its downstream targets, including the splicing factor SFPQ and altering the splicing control.</p></sec></sec><sec id="Sec9"><title>Juvenile atypical PD genes</title><sec id="FPar4"><title>ATP13A2</title><p><italic>ATP13A2</italic> mutations are associated with Kufor&#x02013;Rakeb syndrome, a form of recessively levodopa-responsive inherited atypical parkinsonism [<xref ref-type="bibr" rid="CR103">103</xref>]. It encodes a large protein belonging to the ATPase transmembrane transporters, and recently, it has been identified as a potent modifier of the toxicity induced by alpha-synuclein [<xref ref-type="bibr" rid="CR104">104</xref>].</p><p><italic>ATP13A2</italic> is composed of 29 exons and lies on chromosome 1 covering about 26&#x000a0;kb of genomic DNA. One of the first identified disease-causing mutations was a guanine-to-adenine transition in the donor splice site of exon 13, leading to the skipping of exon 13 and resulting in a deletion of part of the third transmembrane domain [<xref ref-type="bibr" rid="CR105">105</xref>].</p><p>According to data repositories, at least 15 alternatively spliced transcripts are expressed in humans (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The longest transcripts are ATP13A2-001, ATP13A2-002, and ATP13A2-005. Transcript variants ATP13A2-001 and ATP13A2-005 differ only in a nucleotide segment on exon 5, while transcript variant ATP13A2-002 lacks exons 22 and 28. The ATP13A2 mRNA is highly expressed in the brain, particularly in the <italic>substantia nigra</italic> of patients with classical late-onset PD [<xref ref-type="bibr" rid="CR91">91</xref>]. However, nothing is known about the splicing expression profiles of this gene in PD and healthy subjects.</p><p>The products of these transcripts have been studied at the protein level. The isoform 1 encoded by ATP13A2-001 is a protein of 1180 amino acids with ten transmembrane domains. Isoform 2 encoded by ATP13A2-005 contains a five amino acid deletion near the N-terminus, while isoform 3, encoded by ATP13A2-002, contains two deletions, generating a highly diverged C-terminus [<xref ref-type="bibr" rid="CR105">105</xref>]. Functional studies have shown that the isoform 1 is located in the lysosome membrane, whereas the isoform 3 protein is retained in the endoplasmic reticulum and rapidly degraded by the proteasome. In addition, both isoforms 1 and 3 are eliminated via the endoplasmic reticulum-associated degradation pathway [<xref ref-type="bibr" rid="CR105">105</xref>].</p></sec><sec id="FPar5"><title>PLA2G6</title><p>Recessive mutations in the <italic>phospholipase A2 group VI</italic> (<italic>PLA2G6</italic>) gene have been initially described as the cause of infantile neuroaxonal dystrophy and neurodegeneration associated with brain iron accumulation. Recently, this gene has also been associated with a particular parkinsonian phenotype, consisting of levodopa-responsive dystonia, pyramidal signs, and cognitive/psychiatric features, with onset in early adulthood [<xref ref-type="bibr" rid="CR106">106</xref>]. Among <italic>PLA2G6</italic> identified mutations, the c.1077G&#x02009;&#x0003e;&#x02009;A mutation at the last nucleotide of exon 7 (apparently a synonymous mutation) stands out as a cause of abnormal mRNA splicing. This single nucleotide substitution causes the activation of a cryptic splice site producing a 4-bp deleted transcript with altered frame shift in leukocytes [<xref ref-type="bibr" rid="CR106">106</xref>].</p><p><italic>PLA2G6</italic> gene maps on chromosome 22 (q13.1), covering 70&#x000a0;kb of genomic DNA. Several transcript variants encoding multiple isoforms have been described up to now (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The longest <italic>PLA2G6</italic> mRNA PLA2G6-001 includes 17 exonic regions and encodes the 85/88&#x000a0;kDa calcium-independent phospholipase known as A2 isoform a. The other two long transcripts (PLA2G6-002 and PLA2G6-201) differ in the start point, both lack of exon 9 and encode the same protein, called isoform b. The expression profile of this gene in healthy and disease states remains unknown.</p></sec><sec id="FPar6"><title>FBXO7</title><p>Mutations in the <italic>F</italic>-<italic>box only protein 7</italic> (<italic>FBXO7</italic>) gene cause parkinsonian pyramidal disease (PPD- or PARK15-associated parkinsonism), an autosomal recessive neurodegenerative disease with juvenile onset, severe levodopa-response, and additional pyramidal signs. Some pathogenic mutations have been identified (R378G, R498X, and T22M) including a compound heterozygous mutation (IVS7&#x02009;+&#x02009;1G/T) that removes the invariable splice donor of intron 7 and may disrupt <italic>FBXO7</italic> messenger RNA splicing [<xref ref-type="bibr" rid="CR107">107</xref>&#x02013;<xref ref-type="bibr" rid="CR109">109</xref>].</p><p>The <italic>FBXO7</italic> gene, mapped on chromosome 22q12.3, contains nine exons spanning about 24.1&#x000a0;kb. It encodes a 522 amino acid protein consisting of several domains [<xref ref-type="bibr" rid="CR108">108</xref>], which target proteins for ubiquitination [<xref ref-type="bibr" rid="CR108">108</xref>]. Alternatively spliced transcript variants of this gene have been identified (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR107">107</xref>]. FBXO7-001 is the longest and more abundant transcript ubiquitously expressed [<xref ref-type="bibr" rid="CR110">110</xref>], particularly in skin fibroblasts [<xref ref-type="bibr" rid="CR111">111</xref>]. FBXO7-002 arises from an inner alternative exon 1, differs in the start codon, and produces a shorter isoform. Both these encoded protein isoforms have been detected in cells [<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec></sec></sec><sec id="Sec10"><title>X-linked parkinsonism</title><p>X-linked dystonia parkinsonism (XDP) is an X-linked recessive adult-onset movement disorder characterized by both dystonia and parkinsonism. <italic>TATA</italic>-<italic>box binding protein</italic>-<italic>associated factor 1</italic> (<italic>TAF1</italic>) gene, located in the disease locus Xq13.1, has been reported as the first related XPD gene, harboring disease-specific single-nucleotide changes and a small deletion within the multiple transcript panel [<xref ref-type="bibr" rid="CR112">112</xref>]. This gene is part of a complex region of DNA (the TAF1/DYT3 multiple transcript systems), which encompasses the exonic regions of TAF1 gene and further additional downstream exons [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. This system includes multiple different transcription start sites and encodes multiple spliced transcripts and isoforms (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR112">112</xref>].<table-wrap id="Tab3"><label>Table 3</label><caption><p>Alternative splice variants of human X-linked PD genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene name</th><th>Transcript number</th><th>Ensembl name</th><th>Genbank accession number</th><th>Protein length</th></tr></thead><tbody><tr><td rowspan="20">
<italic>TAF1</italic>
</td><td char="." align="char">1.</td><td>TAF1-201</td><td>NM_001286074</td><td char="." align="char">1895 aa</td></tr><tr><td char="." align="char">2.</td><td>TAF1-009</td><td>NM_138923</td><td char="." align="char">1872 aa</td></tr><tr><td char="." align="char">3.</td><td>TAF1-008</td><td>NM_004606</td><td char="." align="char">1893 aa</td></tr><tr><td char="." align="char">4.</td><td>TAF1-014</td><td>&#x02013;</td><td char="." align="char">458 aa</td></tr><tr><td char="." align="char">5.</td><td>TAF1-010</td><td>&#x02013;</td><td char="." align="char">490 aa</td></tr><tr><td char="." align="char">6.</td><td>TAF1-021</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">7.</td><td>TAF1-011</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">8.</td><td>TAF1-013</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">9.</td><td>TAF1-012</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">10.</td><td>TAF1-015</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">11.</td><td>TAF1-018</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">12.</td><td>TAF1-016</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">13.</td><td>TAF1-022</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">14.</td><td>TAF1-023</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">15.</td><td>TAF1-005</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">16.</td><td>TAF1-006</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">17.</td><td>TAF1-020</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">18.</td><td>TAF1-019</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">19.</td><td>TAF1-017</td><td>&#x02013;</td><td char="." align="char">279 aa</td></tr><tr><td char="." align="char">20.</td><td>TAF1-007</td><td>&#x02013;</td><td char="." align="char">150 aa</td></tr><tr><td rowspan="7">
<italic>ATP6AP2</italic>
</td><td char="." align="char">1.</td><td>ATP6AP2-004</td><td>NM_005765</td><td char="." align="char">350 aa</td></tr><tr><td char="." align="char">2.</td><td>ATP6AP2-007</td><td>&#x02013;</td><td char="." align="char">203 aa</td></tr><tr><td char="." align="char">3.</td><td>ATP6AP2-005</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">4.</td><td>ATP6AP2-006</td><td>&#x02013;</td><td char="." align="char">243 aa</td></tr><tr><td char="." align="char">5.</td><td>ATP6AP2-001</td><td>&#x02013;</td><td char="." align="char">259 aa</td></tr><tr><td char="." align="char">6.</td><td>ATP6AP2-003</td><td>&#x02013;</td><td>No protein</td></tr><tr><td char="." align="char">7.</td><td>ATP6AP2-002</td><td>&#x02013;</td><td>No protein</td></tr></tbody></table><table-wrap-foot><p>Gene name, Ensembl transcript names, GenBank accession numbers, and relative encoded amino acidic protein length of splice variants are reported in the table. The number in the column &#x0201c;Transcript number&#x0201d; identifies the transcript in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>
</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Fig. 4</label><caption><p>Structures of the alternative splicing variants of human X-linked PD genes. Structures of the described mRNA splicing variants are represented in the figure as reported in Ensembl library (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/index.html">http://www.ensembl.org/index.html</ext-link>). On the <italic>left</italic>, each variant is indicated with a <italic>number</italic> corresponding to that indicated in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. All transcripts are illustrated in 5&#x02032;-3&#x02032; sense</p></caption><graphic xlink:href="10048_2015_449_Fig4_HTML" id="MO4"/></fig></p><p>Recently, the <italic>ATP6AP2</italic> gene (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) has been proposed as a novel gene for X-linked parkinsonism with spasticity (XPDS) by exome sequencing analysis [<xref ref-type="bibr" rid="CR114">114</xref>]. A silent mutation (p.S115S) in the <italic>ATP6AP2</italic> gene has been identified in one affected individual, resulting in the aberrant splicing of ATP6AP2 mRNA and the overexpression of a minor splice isoform [<xref ref-type="bibr" rid="CR114">114</xref>]. Noteworthy, the ATP6AP2 is an essential accessory component of the vacuolar ATPase required for lysosomal degradative functions and autophagy, a pathway frequently affected in PD.</p></sec><sec id="Sec11"><title>Other PD-related genes</title><sec id="Sec12"><title>SNCAIP</title><p>Synphilin-1, encoded by <italic>SNCAIP</italic> gene, is a presynaptic protein containing several protein&#x02013;protein interaction motifs, including ankyrin-like repeats, a coiled-coil domain, and an ATP/GTP-binding domain [<xref ref-type="bibr" rid="CR115">115</xref>]. It interacts strongly with alpha-synuclein in neuronal tissue and may play a role in the formation of Lewy bodies during neurodegeneration. It is also implicated in parkinsonism as one of the parkin substrates. In addition, some studies have identified <italic>SNCAIP</italic> sequence variants in PD patients and have suggested it as a candidate PD gene [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p><p><italic>SNCAIP</italic> gene maps on chromosome 5 (5q23.2) and spans about 152&#x000a0;kb of genomic DNA. Although the database Gene reports <italic>SNCAIP</italic> composed of 11 exons, additional exonic regions emerge by aligning the sequence of the gene with each transcript. To date, at least 22 alternative spliced transcript variants have been identified (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), but the most studied are synphilin-1 and 1A. Synphilin-1 (SNCAIP-001) is the full-length transcript, while synphilin-1A variant is a shorter form (SNCAIP-201). The latter lacks exons 4 and 5 and contains an extra exon located between exons 10 and 11. Synphilin-1A isoform is thought to be involved in the pathogenesis of PD and may play an important role in the formation of Lewy bodies [<xref ref-type="bibr" rid="CR118">118</xref>&#x02013;<xref ref-type="bibr" rid="CR120">120</xref>]. Interestingly, synphilin-1A protein shows enhanced aggregation properties, which cause neuronal toxicity [<xref ref-type="bibr" rid="CR118">118</xref>&#x02013;<xref ref-type="bibr" rid="CR120">120</xref>].<table-wrap id="Tab4"><label>Table 4</label><caption><p>Alternative splice variants of other human PD-related genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene name</th><th>Transcript number</th><th>Ensembl name</th><th>Genbank accession number</th><th>Protein length</th></tr></thead><tbody><tr><td rowspan="22">
<italic>SNCAIP</italic>
</td><td align="left">1.</td><td>SNCAIP-019</td><td>&#x02013;</td><td align="left">135 aa</td></tr><tr><td align="left">2.</td><td>SNCAIP-003</td><td>&#x02013;</td><td align="left">66 aa</td></tr><tr><td align="left">3.</td><td>SNCAIP-016</td><td>&#x02013;</td><td align="left">161 aa</td></tr><tr><td align="left">4.</td><td>SNCAIP-017</td><td>&#x02013;</td><td align="left">98 aa</td></tr><tr><td align="left">5.</td><td>SNCAIP-010</td><td>&#x02013;</td><td align="left">858 aa</td></tr><tr><td align="left">6.</td><td>SNCAIP-001</td><td>NM_005460</td><td align="left">919 aa</td></tr><tr><td align="left">7.</td><td>SNCAIP-204</td><td>&#x02013;</td><td align="left">113 aa</td></tr><tr><td align="left">8.</td><td>SNCAIP-201</td><td>NM_001242935</td><td align="left">603 aa</td></tr><tr><td align="left">9.</td><td>SNCAIP-004</td><td>&#x02013;</td><td align="left">66 aa</td></tr><tr><td align="left">10.</td><td>SNCAIP-018</td><td>&#x02013;</td><td align="left">68 aa</td></tr><tr><td align="left">11.</td><td>SNCAIP-002</td><td>&#x02013;</td><td align="left">1016 aa</td></tr><tr><td align="left">12.</td><td>SNCAIP-006</td><td>&#x02013;</td><td align="left">62 aa</td></tr><tr><td align="left">13.</td><td>SNCAIP-005</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">14.</td><td>SNCAIP-007</td><td>&#x02013;</td><td align="left">66 aa</td></tr><tr><td align="left">15.</td><td>SNCAIP-203</td><td>&#x02013;</td><td align="left">88 aa</td></tr><tr><td align="left">16.</td><td>SNCAIP-202</td><td>&#x02013;</td><td align="left">62 aa</td></tr><tr><td align="left">17.</td><td>SNCAIP-012</td><td>&#x02013;</td><td align="left">66 aa</td></tr><tr><td align="left">18.</td><td>SNCAIP-011</td><td>&#x02013;</td><td align="left">88 aa</td></tr><tr><td align="left">19.</td><td>SNCAIP-009</td><td>&#x02013;</td><td align="left">588 aa</td></tr><tr><td align="left">20.</td><td>SNCAIP-008</td><td>&#x02013;</td><td align="left">113 aa</td></tr><tr><td align="left">21.</td><td>SNCAIP-015</td><td>&#x02013;</td><td align="left">14 aa</td></tr><tr><td align="left">22.</td><td>SNCAIP-013</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="3">
<italic>MAO</italic>-<italic>B</italic>
</td><td align="left">1.</td><td>MAOB-001</td><td>NM_000898</td><td align="left">520 aa</td></tr><tr><td align="left">2.</td><td>MAOB-002</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">3.</td><td>MAOB-004</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="14">
<italic>GBA</italic>
</td><td align="left">1.</td><td>GBA-011</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">2.</td><td>GBA-001</td><td>NM_000157</td><td align="left">536 aa</td></tr><tr><td align="left">3.</td><td>GBA-002</td><td>NM_001005741; NM_001005742</td><td align="left">536 aa</td></tr><tr><td align="left">4.</td><td>GBA-003</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">5.</td><td>GBA-009</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">6.</td><td>GBA-015</td><td>NM_001171812</td><td align="left">487 aa</td></tr><tr><td align="left">7.</td><td>GBA-016</td><td>NM_001171811</td><td align="left">449 aa</td></tr><tr><td align="left">8.</td><td>GBA-005</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">9.</td><td>GBA-012</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">10.</td><td>GBA-006</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">11.</td><td>GBA-010</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">12.</td><td>GBA-014</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">13.</td><td>GBA-007</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">14.</td><td>GBA-013</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="18">
<italic>MAPT</italic>
</td><td align="left">1.</td><td>MAPT-204</td><td>NM_005910</td><td align="left">441 aa</td></tr><tr><td align="left">2.</td><td>MAPT-202</td><td>NM_001123067</td><td align="left">412 aa</td></tr><tr><td align="left">3.</td><td>MAPT-201</td><td>NM_016835</td><td align="left">758 aa</td></tr><tr><td align="left">4.</td><td>MAPT-205</td><td>NM_001203251; NM_001203252</td><td align="left">410 aa</td></tr><tr><td align="left">5.</td><td>MAPT-203</td><td>NM_001123066</td><td align="left">776 aa</td></tr><tr><td align="left">6.</td><td>MAPT-013</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">7.</td><td>MAPT-001</td><td>NM_016841</td><td align="left">352 aa</td></tr><tr><td align="left">8.</td><td>MAPT-002</td><td>NM_016834</td><td align="left">383 aa</td></tr><tr><td align="left">9.</td><td>MAPT-006</td><td>&#x02013;</td><td align="left">410 aa</td></tr><tr><td align="left">10.</td><td>MAPT-007</td><td>&#x02013;</td><td align="left">441 aa</td></tr><tr><td align="left">11.</td><td>MAPT-008</td><td>&#x02013;</td><td align="left">758 aa</td></tr><tr><td align="left">12.</td><td>MAPT-004</td><td>&#x02013;</td><td align="left">776 aa</td></tr><tr><td align="left">13.</td><td>MAPT-003</td><td>&#x02013;</td><td align="left">412 aa</td></tr><tr><td align="left">14.</td><td>MAPT-009</td><td>&#x02013;</td><td align="left">341 aa</td></tr><tr><td align="left">15.</td><td>MAPT-014</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">16.</td><td>MAPT-011</td><td>&#x02013;</td><td align="left">59 aa</td></tr><tr><td align="left">17.</td><td>MAPT-010</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">18.</td><td>MAPT-012</td><td>&#x02013;</td><td>No protein</td></tr><tr><td rowspan="31">
<italic>SRRM2</italic>
</td><td align="left">1.</td><td>SRRM2-001</td><td>NM_016333</td><td align="left">2752 aa</td></tr><tr><td align="left">2.</td><td>SRRM2-201</td><td>&#x02013;</td><td align="left">311aa</td></tr><tr><td align="left">3.</td><td>SRRM2-003</td><td>&#x02013;</td><td align="left">1018 aa</td></tr><tr><td align="left">4.</td><td>SRRM2-006</td><td>&#x02013;</td><td align="left">297 aa</td></tr><tr><td align="left">5.</td><td>SRRM2-004</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">6.</td><td>SRRM2-007</td><td>&#x02013;</td><td align="left">895 aa</td></tr><tr><td align="left">7.</td><td>SRRM2-011</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">8.</td><td>SRRM2-028</td><td>&#x02013;</td><td align="left">94 aa</td></tr><tr><td align="left">9.</td><td>SRRM2-012</td><td>&#x02013;</td><td align="left">115 aa</td></tr><tr><td align="left">10.</td><td>SRRM2-013</td><td>&#x02013;</td><td align="left">251 aa</td></tr><tr><td align="left">11.</td><td>SRRM2-029</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">12.</td><td>SRRM2-014</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">13.</td><td>SRRM2-030</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">14.</td><td>SRRM2-015</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">15.</td><td>SRRM2-016</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">16.</td><td>SRRM2-017</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">17.</td><td>SRRM2-009</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">18.</td><td>SRRM2-018</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">19.</td><td>SRRM2-019</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">20.</td><td>SRRM2-022</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">21.</td><td>SRRM2-020</td><td>&#x02013;</td><td align="left">184 aa</td></tr><tr><td align="left">22.</td><td>SRRM2-021</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">23.</td><td>SRRM2-023</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">24.</td><td>SRRM2-024</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">25.</td><td>SRRM2-025</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">26.</td><td>SRRM2-026</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">27.</td><td>SRRM2-010</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">28.</td><td>SRRM2-027</td><td>&#x02013;</td><td>No protein</td></tr><tr><td align="left">29.</td><td>SRRM2-031</td><td>&#x02013;</td><td align="left">78 aa</td></tr><tr><td align="left">30</td><td>SRRM2-032</td><td>&#x02013;</td><td align="left">41 aa</td></tr><tr><td align="left">31.</td><td>SRRM2-033</td><td>&#x02013;</td><td>No protein</td></tr></tbody></table><table-wrap-foot><p>Gene name, Ensembl transcript names, GenBank accession numbers and relative encoded amino acidic protein length of splice variants are reported in the table. Number in the column &#x0201c;Transcript number&#x0201d; identifies the transcript in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>
</p></table-wrap-foot></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>Structures of the alternative splicing variants of the other human PD-related genes. Structures of the described mRNA splicing variants are represented in the figure as reported in Ensembl library (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/index.html">http://www.ensembl.org/index.html</ext-link>). On the <italic>left</italic>, each variant is indicated with a <italic>number</italic> corresponding to that indicated in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. All transcripts are illustrated in 5&#x02032;-3&#x02032; sense, except <italic>MAO</italic>-<italic>B</italic> and <italic>GBA</italic> genes, which are illustrated in antisense corresponding to their 3&#x02032;-5&#x02032; sense transcription</p></caption><graphic xlink:href="10048_2015_449_Fig5_HTML" id="MO5"/></fig></p><p>The mRNA expression levels of synphilin 1, 1A, and other two additional synphilin variants have been simultaneously investigated in the frontal cortex of PD patients. Their overall overexpression has been demonstrated when compared to healthy controls [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].</p></sec><sec id="Sec13"><title>MAPT</title><p><italic>MAPT</italic> gene encodes the microtubule-associated protein tau, a protein involved in microtubule assembly and stability [<xref ref-type="bibr" rid="CR121">121</xref>]. It is located on chromosome 17q21 and contains 15 exons. It gives rise to multiple splice transcripts (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) which are differentially expressed in human tissues [<xref ref-type="bibr" rid="CR11">11</xref>]. In the adult human central nervous system, <italic>MAPT</italic> splicing generates six tau isoforms composed of either three or four microtubule-binding repeat motifs in the C-terminal (3R- and 4R-tau).</p><p>A number of mutations within and around <italic>MAPT</italic> exon 10 disrupt exonic and intronic splicing elements as well as the formation of an RNA stem-loop structure at the 5&#x02032; splice site (which normally functions to restrict spliceosome assembly). This event results in an altered ratio of 3R/4R isoforms [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The disruption of the balance between them results in hyperphosphorylation and aggregation of tau proteins into neurofibrillary tangles, causing the frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. These data support a direct relationship between aberrant alternative splicing of tau and neuropathology.</p></sec><sec id="Sec14"><title>GBA</title><p>Mutations in &#x003b2;-glucocerebrosidase (<italic>GBA</italic>) gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. Some studies have identified <italic>GBA</italic> genetic variants as significant risk factors for the development of PD [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p><italic>GBA</italic> gene is located in a gene-rich region on chromosome 1q21. It spans 10.4&#x000a0;kb and contains 12 exons. Currently, there are four annotated alternative transcripts encoding proteins (GBA-001, GBA-002, GBA-015, and GBA-016; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Two of them originate from an alternative promoter located 2.6&#x000a0;kb upstream of the first ATG [<xref ref-type="bibr" rid="CR123">123</xref>]. All transcripts share the same start codon, with the exception of GBA-012, whose open-reading frame starts upon exon 4 and produces a shorter protein isoform. Further transcripts are produced, but they do not encode proteins. The <italic>GBA</italic> splicing profile has not been studied still, and it is unknown if its alternative splicing is involved in PD.</p></sec><sec id="Sec15"><title>MAO-B</title><p><italic>MAO</italic>-<italic>B</italic> gene is located on chromosome X and includes 15 exons (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Although it is not a confirmed susceptibility gene [<xref ref-type="bibr" rid="CR18">18</xref>], increased levels of monoamine oxidase B (MAO) mRNA and enzymatic activity have been reported in platelets from patients with both Parkinson&#x02019;s and Alzheimer&#x02019;s diseases [<xref ref-type="bibr" rid="CR124">124</xref>]. Furthermore, it is well established that MAO-B inhibitors delay progression of both pathologies [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>].</p><p>Several DNA polymorphisms in the <italic>MAO</italic>-<italic>B</italic> gene have been described in populations with distinct ethnic backgrounds [<xref ref-type="bibr" rid="CR124">124</xref>]. A SNP common in all ethnic groups and associated with two-fold risk of PD is the G/A dimorphism in intron 13 sequence [<xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>]. This SNP does not change the coding sequence and does not affect the consensus acceptor and donor sites. However, it has been demonstrated the G/A dimorphism in intron 13 sequence creates a splicing enhancer that stimulates intron 13 removal and a spliceosomal complex assembly and alters splicing factors&#x02019; binding site efficiency [<xref ref-type="bibr" rid="CR124">124</xref>].</p></sec><sec id="Sec16"><title>SRRM2</title><p>Along with <italic>cis</italic>-acting elements, alternative splicing regulation relies on <italic>trans</italic>-splicing factors including the serine/arginine (SR) proteins. One of these proteins, the RNA splicing factor SRRM2 (or serine/arginine repetitive matrix 2), has been identified as the only gene that stood out as differentially expressed in multiple gene expression PD datasets [<xref ref-type="bibr" rid="CR130">130</xref>].</p><p><italic>SRRM2</italic> gene generates two main alternative splicing transcripts different at their 3&#x02032; end (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The full-length isoform SRRM2-001 contains 15 exons, while the shorter isoform SRRM2-003 contains 11 exons and lacks exons 12&#x02013;15. These two isoforms are differentially expressed in postmortem PD brain regions [<xref ref-type="bibr" rid="CR130">130</xref>]. The shorter transcript was upregulated in the <italic>substantia nigra</italic> but unchanged in the <italic>amygdala</italic> of PD patients versus healthy controls. On the contrary, the longer transcript was downregulated in both <italic>substantia nigra</italic> and <italic>amygdala</italic> of PDs as compared to controls [<xref ref-type="bibr" rid="CR130">130</xref>]. Furthermore, in the peripheral blood of patients with PD, SRRM2 short isoform is overexpressed, while the expression of longest isoform is reduced [<xref ref-type="bibr" rid="CR130">130</xref>].</p></sec></sec></sec><sec id="Sec17"><title>Genome-wide RNA expression analysis reveals global alternative splicing changes in PD</title><p>Although a &#x0201c;gene-by-gene&#x0201d; approach may simplify splicing analysis, global alternative splicing changes in PD have to be considered. The majority of the whole gene expression array studies in PD brain regions have unfortunately looked at a single transcript per gene, ignoring the multiple transcripts generated by alternative splicing [<xref ref-type="bibr" rid="CR14">14</xref>]. Nonetheless, mRNA splicing has been identified as a mechanism significantly altered in cortical neurons of PD patients [<xref ref-type="bibr" rid="CR131">131</xref>].</p><p>In order to investigate the splicing expression changes, some studies have used exon arrays. This kind of approach, enabling better monitoring and detection of the alternative splicing events, has allowed to observe significant changes in overall gene splicing in PD blood cells compared to healthy controls [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. Another exon array study has been conducted in blood of advanced PD patients prior to and following deep brain stimulation neurosurgery, a technique that efficiently improves the motor symptoms of PD [<xref ref-type="bibr" rid="CR133">133</xref>]. This analysis has showed preliminary results suggesting brain electrical stimulation may correlate with significant profile changes in nonsense-mediated mRNA decay (an mRNA surveillance process that detects and selectively degrades splice transcripts harboring premature termination codons) in blood cell transcripts [<xref ref-type="bibr" rid="CR133">133</xref>]. Potashkin et al. [<xref ref-type="bibr" rid="CR134">134</xref>] have also used specific splice variant microarrays in PD patients in order to identify mRNAs splice transcripts as molecular biomarkers for an early PD diagnosis. Through this approach, they identified 13 splice variants with an altered expression in early-stage PD patients versus healthy controls [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>].</p><p>A recent technology to better study splicing defects is deep sequencing of RNA (RNAseq) [<xref ref-type="bibr" rid="CR14">14</xref>]. The advantage of RNAseq is that it is theoretically feasible to measure both RNA expression levels and modifications such as splicing. In addition, RNAseq gives the possibility of discovering novel transcripts. Whole transcriptome RNAseq data have been obtained from blood leukocytes of PD patients&#x02019; predeep and postdeep brain stimulation treatment [<xref ref-type="bibr" rid="CR136">136</xref>]. This approach has enabled to discover novel human exons and junctions in protein-coding RNA molecules, as well as a large range of differential splicing events pretreatment and posttreatment compared to healthy controls [<xref ref-type="bibr" rid="CR136">136</xref>]. Although this is the first study using in-depth PD transcriptome sequencing, RNAseq represents a promising technique to better study PD alternative splicing.</p></sec><sec id="Sec18"><title>The role of miRNA and lncRNA in PD alternative splicing modulation</title><p>A large number of alternative exon regions have been predicted as binding sites of microRNAs (miRNAs). The latter is a class of small noncoding RNA molecules, which mainly act as posttranscriptional modulators of multiple target genes by partial sequence complementarity. Through this mechanism, they may also influence splicing process.</p><p>The interplay between miRNA differential expression and alternative splicing modification in PD has been recently investigated [<xref ref-type="bibr" rid="CR137">137</xref>]. Parallel changes in miRNA profiles and their spliced targets have been observed in PD leukocytes and PD-relevant brain regions (including the <italic>substantia nigra</italic> as well as the <italic>frontal lobe</italic>). This study was conducted through coupled analysis of small RNA sequencing data, splice junction arrays, and exon arrays [<xref ref-type="bibr" rid="CR137">137</xref>].</p><p>Another novel fascinating class of RNAs with unknown functions is long noncoding RNAs (lncRNAs), defined as transcripts of over 200 nucleotides. The GENCODE noncoding RNA set collects all lncRNAs known so far, including several spliced transcript shorter than 200&#x000a0;bp. LncRNA profiling has been recently assessed in PD leukocytes predeep and postdeep brain stimulation via RNAseq [<xref ref-type="bibr" rid="CR136">136</xref>]. This survey allowed to identify some lncRNAs overexpressed in PD and inversely decreased following deep brain stimulation [<xref ref-type="bibr" rid="CR136">136</xref>]. Differentially expressed lncRNA includes the spliceosome component U1, supporting the hypothesis of disease-involved splicing modulations [<xref ref-type="bibr" rid="CR136">136</xref>].</p><p>The identification of existing networks between noncoding mRNAs and alternative splicing modifications represents an important step forward the road to understanding the molecular basis of PD.</p></sec><sec id="Sec19" sec-type="conclusion"><title>Conclusions</title><p>Alternative splicing is a highly harmonized process, based on a combination of DNA sequence motifs, intronic and exonic elements, regulatory factors, and temporal and spatial signaling pathways. Mutations that disrupt any of these critical features may alter the finely tuned splicing processes, upsetting the production or functions of the encoded proteins, and finally causing human diseases. Assessing the alternative splicing modulation of PD-related genes represents an important point to understand PD molecular etiology. Future studies, both with the standard or the new currently available large-scale techniques, will offer a complete data pool of the alternative splicing events in PD and will provide new possible insights in order to develop strategies for PD therapy and diagnosis.</p></sec></body><back><ack><p>This study was supported by the international Ph.D. program in Neuroscience of the University of Catania. We also gratefully acknowledge Cristina Cal&#x000ec;, Alfia Corsino, Maria Patrizia D&#x02019;Angelo, and Francesco Marino for their administrative and technical support.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>AJ</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name></person-group><article-title>The pathobiology of splicing</article-title><source>J Pathol</source><year>2010</year><volume>220</volume><issue>2</issue><fpage>152</fpage><lpage>163</lpage><?supplied-pmid 19918805?><pub-id pub-id-type="pmid">19918805</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>K</given-names></name><name><surname>Makeyev</surname><given-names>EV</given-names></name></person-group><article-title>Regulation of gene expression in mammalian nervous system through alternative pre-mRNA splicing coupled with RNA quality control mechanisms</article-title><source>Mol Cell Neurosci</source><year>2013</year><volume>56</volume><fpage>420</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2013.01.003</pub-id><?supplied-pmid 23357783?><pub-id pub-id-type="pmid">23357783</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calarco</surname><given-names>JA</given-names></name><name><surname>Zhen</surname><given-names>M</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><article-title>Networking in a global world: establishing functional connections between neural splicing regulators and their target transcripts</article-title><source>RNA</source><year>2011</year><volume>17</volume><issue>5</issue><fpage>775</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1261/rna.2603911</pub-id><?supplied-pmid 21415141?><pub-id pub-id-type="pmid">21415141</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>JA</given-names></name><name><surname>Black</surname><given-names>DL</given-names></name></person-group><article-title>Neuronal regulation of alternative pre-mRNA splicing</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><issue>11</issue><fpage>819</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1038/nrn2237</pub-id><?supplied-pmid 17895907?><pub-id pub-id-type="pmid">17895907</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Shai</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>LJ</given-names></name><name><surname>Frey</surname><given-names>BJ</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><article-title>Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><issue>12</issue><fpage>1413</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1038/ng.259</pub-id><?supplied-pmid 18978789?><pub-id pub-id-type="pmid">18978789</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behzadnia</surname><given-names>N</given-names></name><name><surname>Golas</surname><given-names>MM</given-names></name><name><surname>Hartmuth</surname><given-names>K</given-names></name><name><surname>Sander</surname><given-names>B</given-names></name><name><surname>Kastner</surname><given-names>B</given-names></name><name><surname>Deckert</surname><given-names>J</given-names></name><name><surname>Dube</surname><given-names>P</given-names></name><name><surname>Will</surname><given-names>CL</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Stark</surname><given-names>H</given-names></name><name><surname>Luhrmann</surname><given-names>R</given-names></name></person-group><article-title>Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes</article-title><source>EMBO J</source><year>2007</year><volume>26</volume><issue>6</issue><fpage>1737</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601631</pub-id><?supplied-pmid 17332742?><pub-id pub-id-type="pmid">17332742</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shefer</surname><given-names>K</given-names></name><name><surname>Sperling</surname><given-names>J</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name></person-group><article-title>The supraspliceosome&#x02014;a multi-task machine for regulated pre-mRNA processing in the cell nucleus</article-title><source>Comput Struct Biotechnol J</source><year>2014</year><volume>11</volume><issue>19</issue><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2014.09.008</pub-id><?supplied-pmid 25408845?><pub-id pub-id-type="pmid">25408845</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamazon</surname><given-names>ER</given-names></name><name><surname>Stranger</surname><given-names>BE</given-names></name></person-group><article-title>Genomics of alternative splicing: evolution, development and pathophysiology</article-title><source>Hum Genet</source><year>2014</year><volume>133</volume><issue>6</issue><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1007/s00439-013-1411-3</pub-id><?supplied-pmid 24378600?><pub-id pub-id-type="pmid">24378600</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scuderi</surname><given-names>S</given-names></name><name><surname>La Cognata</surname><given-names>V</given-names></name><name><surname>Drago</surname><given-names>F</given-names></name><name><surname>Cavallaro</surname><given-names>S</given-names></name><name><surname>D&#x02019;Agata</surname><given-names>V</given-names></name></person-group><article-title>Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>690796</fpage><pub-id pub-id-type="doi">10.1155/2014/690796</pub-id><?supplied-pmid 25136611?><pub-id pub-id-type="pmid">25136611</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licatalosi</surname><given-names>DD</given-names></name><name><surname>Darnell</surname><given-names>RB</given-names></name></person-group><article-title>Splicing regulation in neurologic disease</article-title><source>Neuron</source><year>2006</year><volume>52</volume><issue>1</issue><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.017</pub-id><?supplied-pmid 17015229?><pub-id pub-id-type="pmid">17015229</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tazi</surname><given-names>J</given-names></name><name><surname>Bakkour</surname><given-names>N</given-names></name><name><surname>Stamm</surname><given-names>S</given-names></name></person-group><article-title>Alternative splicing and disease</article-title><source>Biochim Biophys Acta</source><year>2009</year><volume>1792</volume><issue>1</issue><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2008.09.017</pub-id><?supplied-pmid 18992329?><pub-id pub-id-type="pmid">18992329</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>RK</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name></person-group><article-title>Pre-mRNA splicing in disease and therapeutics</article-title><source>Trends Mol Med</source><year>2012</year><volume>18</volume><issue>8</issue><fpage>472</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2012.06.006</pub-id><?supplied-pmid 22819011?><pub-id pub-id-type="pmid">22819011</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>TA</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><article-title>RNA and disease</article-title><source>Cell</source><year>2009</year><volume>136</volume><issue>4</issue><fpage>777</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.02.011</pub-id><?supplied-pmid 19239895?><pub-id pub-id-type="pmid">19239895</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>PA</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name></person-group><article-title>Gene expression in the Parkinson&#x02019;s disease brain</article-title><source>Brain Res Bull</source><year>2012</year><volume>88</volume><issue>4</issue><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2011.11.016</pub-id><?supplied-pmid 22173063?><pub-id pub-id-type="pmid">22173063</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V</given-names></name></person-group><article-title>Genetics of Parkinson&#x02019;s disease&#x02014;state of the art, 2013</article-title><source>Parkinsonism Relat Disord</source><year>2014</year><volume>20</volume><issue>1</issue><fpage>S23</fpage><lpage>S28</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(13)70009-9</pub-id><?supplied-pmid 24262182?><pub-id pub-id-type="pmid">24262182</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubbe</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>HR</given-names></name></person-group><article-title>Recent advances in Parkinson&#x02019;s disease genetics</article-title><source>J Neurol</source><year>2014</year><volume>261</volume><issue>2</issue><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1007/s00415-013-7003-2</pub-id><?supplied-pmid 23798000?><pub-id pub-id-type="pmid">23798000</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>J</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name></person-group><article-title>Advances in the genetics of Parkinson disease</article-title><source>Nat Rev Neurol</source><year>2013</year><volume>9</volume><issue>8</issue><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2013.132</pub-id><?supplied-pmid 23857047?><pub-id pub-id-type="pmid">23857047</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Lill</surname><given-names>CM</given-names></name><name><surname>Do</surname><given-names>CB</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Kara</surname><given-names>E</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>MF</given-names></name><name><surname>Arepalli</surname><given-names>S</given-names></name><name><surname>Letson</surname><given-names>C</given-names></name><name><surname>Edsall</surname><given-names>C</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Pliner</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><collab>International Parkinson&#x02019;s Disease Genomics C, Parkinson&#x02019;s Study Group Parkinson&#x02019;s Research: The Organized GI, andMe, GenePd, NeuroGenetics Research C, Hussman Institute of Human G, Ashkenazi Jewish Dataset I, Cohorts for H, Aging Research in Genetic E, North American Brain Expression C, United Kingdom Brain Expression C, Greek Parkinson&#x02019;s Disease C, Alzheimer Genetic Analysis G</collab><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Hadjigeorgiou</surname><given-names>GM</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Perlmutter</surname><given-names>JS</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Fiske</surname><given-names>B</given-names></name><name><surname>Sutherland</surname><given-names>M</given-names></name><name><surname>Xiromerisiou</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Clark</surname><given-names>LN</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name></person-group><article-title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x02019;s disease</article-title><source>Nat Genet</source><year>2014</year><volume>46</volume><issue>9</issue><fpage>989</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/ng.3043</pub-id><?supplied-pmid 25064009?><pub-id pub-id-type="pmid">25064009</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanis</surname><given-names>L</given-names></name></person-group><article-title>Alpha-synuclein in Parkinson&#x02019;s disease</article-title><source>Cold Spring Harb Perspect Med</source><year>2012</year><volume>2</volume><issue>2</issue><fpage>a009399</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a009399</pub-id><?supplied-pmid 22355802?><pub-id pub-id-type="pmid">22355802</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pihlstrom</surname><given-names>L</given-names></name><name><surname>Toft</surname><given-names>M</given-names></name></person-group><article-title>Genetic variability in SNCA and Parkinson&#x02019;s disease</article-title><source>Neurogenetics</source><year>2011</year><volume>12</volume><issue>4</issue><fpage>283</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1007/s10048-011-0292-7</pub-id><?supplied-pmid 21800132?><pub-id pub-id-type="pmid">21800132</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name></person-group><article-title>Genetic variants and animal models in SNCA and Parkinson disease</article-title><source>Ageing Res Rev</source><year>2014</year><volume>15C</volume><fpage>161</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2014.04.002</pub-id><pub-id pub-id-type="pmid">24768741</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuytemans</surname><given-names>K</given-names></name><name><surname>Meeus</surname><given-names>B</given-names></name><name><surname>Crosiers</surname><given-names>D</given-names></name><name><surname>Brouwers</surname><given-names>N</given-names></name><name><surname>Goossens</surname><given-names>D</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Pals</surname><given-names>P</given-names></name><name><surname>Pickut</surname><given-names>B</given-names></name><name><surname>Van den Broeck</surname><given-names>M</given-names></name><name><surname>Corsmit</surname><given-names>E</given-names></name><name><surname>Cras</surname><given-names>P</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Del-Favero</surname><given-names>J</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Theuns</surname><given-names>J</given-names></name></person-group><article-title>Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population</article-title><source>Hum Mutat</source><year>2009</year><volume>30</volume><issue>7</issue><fpage>1054</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1002/humu.21007</pub-id><?supplied-pmid 19405094?><pub-id pub-id-type="pmid">19405094</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Domingo-Sabat</surname><given-names>M</given-names></name><name><surname>Lao</surname><given-names>JI</given-names></name><name><surname>Carrato</surname><given-names>C</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Ariza</surname><given-names>A</given-names></name></person-group><article-title>Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases</article-title><source>Neurogenetics</source><year>2008</year><volume>9</volume><issue>1</issue><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s10048-007-0106-0</pub-id><?supplied-pmid 17955272?><pub-id pub-id-type="pmid">17955272</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Domingo-Sabat</surname><given-names>M</given-names></name><name><surname>Humbert</surname><given-names>J</given-names></name><name><surname>Carrato</surname><given-names>C</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Ariza</surname><given-names>A</given-names></name></person-group><article-title>Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease</article-title><source>Neurogenetics</source><year>2008</year><volume>9</volume><issue>3</issue><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/s10048-008-0124-6</pub-id><?supplied-pmid 18335262?><pub-id pub-id-type="pmid">18335262</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>JR</given-names></name><name><surname>Hallett</surname><given-names>PJ</given-names></name><name><surname>Cooper</surname><given-names>O</given-names></name><name><surname>Stanley</surname><given-names>M</given-names></name><name><surname>Isacson</surname><given-names>O</given-names></name></person-group><article-title>Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson&#x02019;s disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression</article-title><source>Mol Cell Neurosci</source><year>2012</year><volume>49</volume><issue>2</issue><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2011.11.006</pub-id><?supplied-pmid 22155155?><pub-id pub-id-type="pmid">22155155</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardo</surname><given-names>LF</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>de Mena</surname><given-names>L</given-names></name><name><surname>Ribacoba</surname><given-names>R</given-names></name><name><surname>Mata</surname><given-names>IF</given-names></name><name><surname>Menendez</surname><given-names>M</given-names></name><name><surname>Moris</surname><given-names>G</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name></person-group><article-title>Alpha-synuclein transcript isoforms in three different brain regions from Parkinson&#x02019;s disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms</article-title><source>Neurosci Lett</source><year>2014</year><volume>562</volume><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2014.01.009</pub-id><?supplied-pmid 24418406?><pub-id pub-id-type="pmid">24418406</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Lao</surname><given-names>JI</given-names></name><name><surname>Carrato</surname><given-names>C</given-names></name><name><surname>Mate</surname><given-names>JL</given-names></name><name><surname>Lopez</surname><given-names>D</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Ariza</surname><given-names>A</given-names></name></person-group><article-title>Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies</article-title><source>Neuropathol Appl Neurobiol</source><year>2004</year><volume>30</volume><issue>6</issue><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2004.00572.x</pub-id><?supplied-pmid 15541000?><pub-id pub-id-type="pmid">15541000</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Humbert</surname><given-names>J</given-names></name><name><surname>Ferrer</surname><given-names>A</given-names></name><name><surname>Lao</surname><given-names>JI</given-names></name><name><surname>Carrato</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>D</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Ariza</surname><given-names>A</given-names></name></person-group><article-title>Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease</article-title><source>Neuroreport</source><year>2006</year><volume>17</volume><issue>12</issue><fpage>1327</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1097/01.wnr.0000224773.66904.e7</pub-id><?supplied-pmid 16951579?><pub-id pub-id-type="pmid">16951579</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Linnertz</surname><given-names>C</given-names></name><name><surname>Saucier</surname><given-names>L</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><name><surname>Hulette</surname><given-names>CM</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><name><surname>Chiba-Falek</surname><given-names>O</given-names></name></person-group><article-title>The effect of SNCA 3&#x02032; region on the levels of SNCA-112 splicing variant</article-title><source>Neurogenetics</source><year>2011</year><volume>12</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s10048-010-0263-4</pub-id><?supplied-pmid 21046180?><pub-id pub-id-type="pmid">21046180</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalivendi</surname><given-names>SV</given-names></name><name><surname>Yedlapudi</surname><given-names>D</given-names></name><name><surname>Hillard</surname><given-names>CJ</given-names></name><name><surname>Kalyanaraman</surname><given-names>B</given-names></name></person-group><article-title>Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson&#x02019;s disease</article-title><source>Free Radic Biol Med</source><year>2010</year><volume>48</volume><issue>3</issue><fpage>377</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.10.045</pub-id><?supplied-pmid 19857570?><pub-id pub-id-type="pmid">19857570</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhinn</surname><given-names>H</given-names></name><name><surname>Qiang</surname><given-names>L</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Rhee</surname><given-names>D</given-names></name><name><surname>Zolin</surname><given-names>A</given-names></name><name><surname>Vanti</surname><given-names>W</given-names></name><name><surname>Abeliovich</surname><given-names>A</given-names></name></person-group><article-title>Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson&#x02019;s disease pathology</article-title><source>Nat Commun</source><year>2012</year><volume>3</volume><fpage>1084</fpage><pub-id pub-id-type="doi">10.1038/ncomms2032</pub-id><?supplied-pmid 23011138?><pub-id pub-id-type="pmid">23011138</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>K</given-names></name></person-group><article-title>Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers</article-title><source>Acta Neuropathol</source><year>2006</year><volume>112</volume><issue>3</issue><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/s00401-006-0104-6</pub-id><?supplied-pmid 16845533?><pub-id pub-id-type="pmid">16845533</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bungeroth</surname><given-names>M</given-names></name><name><surname>Appenzeller</surname><given-names>S</given-names></name><name><surname>Regulin</surname><given-names>A</given-names></name><name><surname>Volker</surname><given-names>W</given-names></name><name><surname>Lorenzen</surname><given-names>I</given-names></name><name><surname>Grotzinger</surname><given-names>J</given-names></name><name><surname>Pendziwiat</surname><given-names>M</given-names></name><name><surname>Kuhlenbaumer</surname><given-names>G</given-names></name></person-group><article-title>Differential aggregation properties of alpha-synuclein isoforms</article-title><source>Neurobiol Aging</source><year>2014</year><volume>35</volume><issue>8</issue><fpage>1913</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.02.009</pub-id><?supplied-pmid 24629672?><pub-id pub-id-type="pmid">24629672</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Tsetsenis</surname><given-names>T</given-names></name><name><surname>Buchman</surname><given-names>V</given-names></name><name><surname>Etherton</surname><given-names>MR</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro</article-title><source>Science</source><year>2010</year><volume>329</volume><issue>5999</issue><fpage>1663</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1126/science.1195227</pub-id><?supplied-pmid 20798282?><pub-id pub-id-type="pmid">20798282</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rideout</surname><given-names>HJ</given-names></name><name><surname>Stefanis</surname><given-names>L</given-names></name></person-group><article-title>The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson&#x02019;s disease</article-title><source>Neurochem Res</source><year>2014</year><volume>39</volume><issue>3</issue><fpage>576</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1007/s11064-013-1073-5</pub-id><?supplied-pmid 23729298?><pub-id pub-id-type="pmid">23729298</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name><name><surname>Crews</surname><given-names>C</given-names></name><name><surname>Britton</surname><given-names>A</given-names></name><name><surname>Malkani</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>EW</given-names></name><name><surname>McInerney-Leo</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Nussbaum</surname><given-names>RL</given-names></name><name><surname>Foote</surname><given-names>KD</given-names></name><name><surname>Mandel</surname><given-names>RJ</given-names></name><name><surname>Crawley</surname><given-names>A</given-names></name><name><surname>Reimsnider</surname><given-names>S</given-names></name><name><surname>Fernandez</surname><given-names>HH</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Gwinn-Hardy</surname><given-names>K</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name></person-group><article-title>Comprehensive screening of a North American Parkinson&#x02019;s disease cohort for LRRK2 mutation</article-title><source>Neurodegener Dis</source><year>2007</year><volume>4</volume><issue>5</issue><fpage>386</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1159/000105160</pub-id><?supplied-pmid 17622782?><pub-id pub-id-type="pmid">17622782</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skipper</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Chua</surname><given-names>E</given-names></name><name><surname>Bonnard</surname><given-names>C</given-names></name><name><surname>Kolatkar</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>LC</given-names></name><name><surname>Jamora</surname><given-names>RD</given-names></name><name><surname>Puvan</surname><given-names>K</given-names></name><name><surname>Puong</surname><given-names>KY</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Pavanni</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>MC</given-names></name><name><surname>Yuen</surname><given-names>Y</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Tan</surname><given-names>EK</given-names></name></person-group><article-title>Analysis of LRRK2 functional domains in nondominant Parkinson disease</article-title><source>Neurology</source><year>2005</year><volume>65</volume><issue>8</issue><fpage>1319</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000180517.70572.37</pub-id><?supplied-pmid 16247070?><pub-id pub-id-type="pmid">16247070</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Mosley</surname><given-names>AD</given-names></name><name><surname>Roberts</surname><given-names>JW</given-names></name><name><surname>Leis</surname><given-names>BC</given-names></name><name><surname>Yearout</surname><given-names>D</given-names></name><name><surname>Raskind</surname><given-names>WH</given-names></name><name><surname>Griffith</surname><given-names>A</given-names></name></person-group><article-title>A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations</article-title><source>Neurology</source><year>2005</year><volume>65</volume><issue>5</issue><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000172630.22804.73</pub-id><?supplied-pmid 16157909?><pub-id pub-id-type="pmid">16157909</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shojaee</surname><given-names>S</given-names></name><name><surname>Sina</surname><given-names>F</given-names></name><name><surname>Farboodi</surname><given-names>N</given-names></name><name><surname>Fazlali</surname><given-names>Z</given-names></name><name><surname>Ghazavi</surname><given-names>F</given-names></name><name><surname>Ghorashi</surname><given-names>SA</given-names></name><name><surname>Parsa</surname><given-names>K</given-names></name><name><surname>Sadeghi</surname><given-names>H</given-names></name><name><surname>Shahidi</surname><given-names>GA</given-names></name><name><surname>Ronaghi</surname><given-names>M</given-names></name><name><surname>Elahi</surname><given-names>E</given-names></name></person-group><article-title>A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson&#x02019;s disease patients</article-title><source>Mov Disord</source><year>2009</year><volume>24</volume><issue>7</issue><fpage>1023</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1002/mds.22503</pub-id><?supplied-pmid 19353692?><pub-id pub-id-type="pmid">19353692</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fonzo</surname><given-names>A</given-names></name><name><surname>Tassorelli</surname><given-names>C</given-names></name><name><surname>De Mari</surname><given-names>M</given-names></name><name><surname>Chien</surname><given-names>HF</given-names></name><name><surname>Ferreira</surname><given-names>J</given-names></name><name><surname>Rohe</surname><given-names>CF</given-names></name><name><surname>Riboldazzi</surname><given-names>G</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Albani</surname><given-names>G</given-names></name><name><surname>Mauro</surname><given-names>A</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><name><surname>Abbruzzese</surname><given-names>G</given-names></name><name><surname>Lopiano</surname><given-names>L</given-names></name><name><surname>Fincati</surname><given-names>E</given-names></name><name><surname>Guidi</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>P</given-names></name><name><surname>Stocchi</surname><given-names>F</given-names></name><name><surname>Onofrj</surname><given-names>M</given-names></name><name><surname>Toni</surname><given-names>V</given-names></name><name><surname>Tinazzi</surname><given-names>M</given-names></name><name><surname>Fabbrini</surname><given-names>G</given-names></name><name><surname>Lamberti</surname><given-names>P</given-names></name><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name><name><surname>Leitner</surname><given-names>P</given-names></name><name><surname>Uitti</surname><given-names>RJ</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Simons</surname><given-names>EJ</given-names></name><name><surname>Breedveld</surname><given-names>GJ</given-names></name><name><surname>Goldwurm</surname><given-names>S</given-names></name><name><surname>Pezzoli</surname><given-names>G</given-names></name><name><surname>Sampaio</surname><given-names>C</given-names></name><name><surname>Barbosa</surname><given-names>E</given-names></name><name><surname>Martignoni</surname><given-names>E</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Italian Parkinson&#x02019;s Genetics</surname><given-names>N</given-names></name></person-group><article-title>Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson&#x02019;s disease</article-title><source>Eur J Hum Genet</source><year>2006</year><volume>14</volume><issue>3</issue><fpage>322</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201539</pub-id><?supplied-pmid 16333314?><pub-id pub-id-type="pmid">16333314</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>DA</given-names></name><name><surname>Racacho</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Panisset</surname><given-names>M</given-names></name><name><surname>Bulman</surname><given-names>DE</given-names></name></person-group><article-title>LRRK2 screening in a Canadian Parkinson&#x02019;s disease cohort</article-title><source>Can J Neurol Sci</source><year>2007</year><volume>34</volume><issue>3</issue><fpage>336</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1017/S0317167100006788</pub-id><?supplied-pmid 17803033?><pub-id pub-id-type="pmid">17803033</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name><name><surname>Nath</surname><given-names>P</given-names></name><name><surname>Washecka</surname><given-names>N</given-names></name><name><surname>Gibbs</surname><given-names>JR</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name></person-group><article-title>Comprehensive analysis of LRRK2 in publicly available Parkinson&#x02019;s disease cases and neurologically normal controls</article-title><source>Hum Mutat</source><year>2008</year><volume>29</volume><issue>4</issue><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1002/humu.20668</pub-id><?supplied-pmid 18213618?><pub-id pub-id-type="pmid">18213618</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Condroyer</surname><given-names>C</given-names></name><name><surname>Lannuzel</surname><given-names>A</given-names></name><name><surname>Lohmann</surname><given-names>E</given-names></name><name><surname>Troiano</surname><given-names>A</given-names></name><name><surname>Tison</surname><given-names>F</given-names></name><name><surname>Damier</surname><given-names>P</given-names></name><name><surname>Thobois</surname><given-names>S</given-names></name><name><surname>Ouvrard-Hernandez</surname><given-names>AM</given-names></name><name><surname>Rivaud-Pechoux</surname><given-names>S</given-names></name><name><surname>Brefel-Courbon</surname><given-names>C</given-names></name><name><surname>Destee</surname><given-names>A</given-names></name><name><surname>Tranchant</surname><given-names>C</given-names></name><name><surname>Romana</surname><given-names>M</given-names></name><name><surname>Leclere</surname><given-names>L</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><collab>French Parkinson&#x02019;s Disease Genetics Study G</collab></person-group><article-title>Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson&#x02019;s disease</article-title><source>J Med Genet</source><year>2009</year><volume>46</volume><issue>7</issue><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1136/jmg.2008.062612</pub-id><?supplied-pmid 19357115?><pub-id pub-id-type="pmid">19357115</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trabzuni</surname><given-names>D</given-names></name><name><surname>Ryten</surname><given-names>M</given-names></name><name><surname>Emmett</surname><given-names>W</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Lackner</surname><given-names>KJ</given-names></name><name><surname>Zeller</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>PA</given-names></name><name><surname>Mamais</surname><given-names>A</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>International Parkinson Disease Genomics</surname><given-names>C</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Garnier</surname><given-names>S</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Simon-Sanchez</surname><given-names>J</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Schadt</surname><given-names>E</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Bandopadhyay</surname><given-names>R</given-names></name><name><surname>Weale</surname><given-names>ME</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name></person-group><article-title>Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>8</issue><fpage>e70724</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0070724</pub-id><?supplied-pmid 23967090?><pub-id pub-id-type="pmid">23967090</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giesert</surname><given-names>F</given-names></name><name><surname>Hofmann</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>A</given-names></name><name><surname>Zerle</surname><given-names>J</given-names></name><name><surname>Kloos</surname><given-names>K</given-names></name><name><surname>Hafen</surname><given-names>U</given-names></name><name><surname>Ernst</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Vogt-Weisenhorn</surname><given-names>DM</given-names></name><name><surname>Wurst</surname><given-names>W</given-names></name></person-group><article-title>Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e63778</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0063778</pub-id><?supplied-pmid 23675505?><pub-id pub-id-type="pmid">23675505</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>D</given-names></name><name><surname>Kwok</surname><given-names>KH</given-names></name><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Lim</surname><given-names>AY</given-names></name><name><surname>Aw</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Lufkin</surname><given-names>T</given-names></name><name><surname>Jesuthasan</surname><given-names>S</given-names></name><name><surname>Sinnakaruppan</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Deletion of the WD40 domain of LRRK2 in zebrafish causes parkinsonism-like loss of neurons and locomotive defect</article-title><source>PLoS Genet</source><year>2010</year><volume>6</volume><issue>4</issue><fpage>e1000914</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1000914</pub-id><?supplied-pmid 20421934?><pub-id pub-id-type="pmid">20421934</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilarino-Guell</surname><given-names>C</given-names></name><name><surname>Wider</surname><given-names>C</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Dachsel</surname><given-names>JC</given-names></name><name><surname>Kachergus</surname><given-names>JM</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>Soto-Ortolaza</surname><given-names>AI</given-names></name><name><surname>Cobb</surname><given-names>SA</given-names></name><name><surname>Wilhoite</surname><given-names>GJ</given-names></name><name><surname>Bacon</surname><given-names>JA</given-names></name><name><surname>Behrouz</surname><given-names>B</given-names></name><name><surname>Melrose</surname><given-names>HL</given-names></name><name><surname>Hentati</surname><given-names>E</given-names></name><name><surname>Puschmann</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Conibear</surname><given-names>E</given-names></name><name><surname>Wasserman</surname><given-names>WW</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name><name><surname>Burkhard</surname><given-names>PR</given-names></name><name><surname>Djaldetti</surname><given-names>R</given-names></name><name><surname>Ghika</surname><given-names>J</given-names></name><name><surname>Hentati</surname><given-names>F</given-names></name><name><surname>Krygowska-Wajs</surname><given-names>A</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><name><surname>Rajput</surname><given-names>A</given-names></name><name><surname>Rajput</surname><given-names>AH</given-names></name><name><surname>Solida</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>RM</given-names></name><name><surname>Uitti</surname><given-names>RJ</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Vingerhoets</surname><given-names>F</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name></person-group><article-title>VPS35 mutations in Parkinson disease</article-title><source>Am J Hum Genet</source><year>2011</year><volume>89</volume><issue>1</issue><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.001</pub-id><?supplied-pmid 21763482?><pub-id pub-id-type="pmid">21763482</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimprich</surname><given-names>A</given-names></name><name><surname>Benet-Pages</surname><given-names>A</given-names></name><name><surname>Struhal</surname><given-names>W</given-names></name><name><surname>Graf</surname><given-names>E</given-names></name><name><surname>Eck</surname><given-names>SH</given-names></name><name><surname>Offman</surname><given-names>MN</given-names></name><name><surname>Haubenberger</surname><given-names>D</given-names></name><name><surname>Spielberger</surname><given-names>S</given-names></name><name><surname>Schulte</surname><given-names>EC</given-names></name><name><surname>Lichtner</surname><given-names>P</given-names></name><name><surname>Rossle</surname><given-names>SC</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Wolf</surname><given-names>E</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Pirker</surname><given-names>W</given-names></name><name><surname>Presslauer</surname><given-names>S</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Katzenschlager</surname><given-names>R</given-names></name><name><surname>Foki</surname><given-names>T</given-names></name><name><surname>Hotzy</surname><given-names>C</given-names></name><name><surname>Reinthaler</surname><given-names>E</given-names></name><name><surname>Harutyunyan</surname><given-names>A</given-names></name><name><surname>Kralovics</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Zimprich</surname><given-names>F</given-names></name><name><surname>Brucke</surname><given-names>T</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Auff</surname><given-names>E</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Rost</surname><given-names>B</given-names></name><name><surname>Ransmayr</surname><given-names>G</given-names></name><name><surname>Winkelmann</surname><given-names>J</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name></person-group><article-title>A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease</article-title><source>Am J Hum Genet</source><year>2011</year><volume>89</volume><issue>1</issue><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.008</pub-id><?supplied-pmid 21763483?><pub-id pub-id-type="pmid">21763483</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraeten</surname><given-names>A</given-names></name><name><surname>Wauters</surname><given-names>E</given-names></name><name><surname>Crosiers</surname><given-names>D</given-names></name><name><surname>Meeus</surname><given-names>B</given-names></name><name><surname>Corsmit</surname><given-names>E</given-names></name><name><surname>Elinck</surname><given-names>E</given-names></name><name><surname>Mattheijssens</surname><given-names>M</given-names></name><name><surname>Peeters</surname><given-names>K</given-names></name><name><surname>Cras</surname><given-names>P</given-names></name><name><surname>Pickut</surname><given-names>B</given-names></name><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Theuns J (2012) Contribution of VPS35 genetic variability to LBD in the Flanders&#x02013;Belgian population</article-title><source>Neurobiol Aging</source><year>1844</year><volume>33</volume><issue>8</issue><fpage>e1811</fpage><lpage>e1843</lpage></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V</given-names></name></person-group><article-title>Autosomal recessive parkinsonism</article-title><source>Parkinsonism Relat Disord</source><year>2012</year><volume>18</volume><issue>1</issue><fpage>S4</fpage><lpage>S6</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(11)70004-9</pub-id><?supplied-pmid 22166450?><pub-id pub-id-type="pmid">22166450</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucking</surname><given-names>CB</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Vaughan</surname><given-names>J</given-names></name><name><surname>De Michele</surname><given-names>G</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Harhangi</surname><given-names>BS</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name><name><surname>Denefle</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><collab>French Parkinson&#x02019;s Disease Genetics Study G, European Consortium on Genetic Susceptibility in Parkinson&#x02019;s D</collab></person-group><article-title>Association between early-onset Parkinson&#x02019;s disease and mutations in the parkin gene</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>21</issue><fpage>1560</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005253422103</pub-id><?supplied-pmid 10824074?><pub-id pub-id-type="pmid">10824074</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Nance</surname><given-names>MA</given-names></name><name><surname>Watts</surname><given-names>RL</given-names></name><name><surname>Hubble</surname><given-names>JP</given-names></name><name><surname>Koller</surname><given-names>WC</given-names></name><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Hiner</surname><given-names>BC</given-names></name><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Allen</surname><given-names>FH</given-names><suffix>Jr</suffix></name><name><surname>Scott</surname><given-names>BL</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Mastaglia</surname><given-names>F</given-names></name><name><surname>Stajich</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Booze</surname><given-names>MW</given-names></name><name><surname>Winn</surname><given-names>MP</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name></person-group><article-title>Parkin mutations and susceptibility alleles in late-onset Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>2003</year><volume>53</volume><issue>5</issue><fpage>624</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1002/ana.10524</pub-id><?supplied-pmid 12730996?><pub-id pub-id-type="pmid">12730996</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illarioshkin</surname><given-names>SN</given-names></name><name><surname>Periquet</surname><given-names>M</given-names></name><name><surname>Rawal</surname><given-names>N</given-names></name><name><surname>Lucking</surname><given-names>CB</given-names></name><name><surname>Zagorovskaya</surname><given-names>TB</given-names></name><name><surname>Slominsky</surname><given-names>PA</given-names></name><name><surname>Miloserdova</surname><given-names>OV</given-names></name><name><surname>Markova</surname><given-names>ED</given-names></name><name><surname>Limborska</surname><given-names>SA</given-names></name><name><surname>Ivanova-Smolenskaya</surname><given-names>IA</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group><article-title>Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism</article-title><source>Mov Disord</source><year>2003</year><volume>18</volume><issue>8</issue><fpage>914</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1002/mds.10467</pub-id><?supplied-pmid 12889082?><pub-id pub-id-type="pmid">12889082</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pigullo</surname><given-names>S</given-names></name><name><surname>De Luca</surname><given-names>A</given-names></name><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Marchese</surname><given-names>R</given-names></name><name><surname>Bellone</surname><given-names>E</given-names></name><name><surname>Colosimo</surname><given-names>A</given-names></name><name><surname>Scaglione</surname><given-names>C</given-names></name><name><surname>Martinelli</surname><given-names>P</given-names></name><name><surname>Di Maria</surname><given-names>E</given-names></name><name><surname>Pizzuti</surname><given-names>A</given-names></name><name><surname>Abbruzzese</surname><given-names>G</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Ajmar</surname><given-names>F</given-names></name><name><surname>Mandich</surname><given-names>P</given-names></name></person-group><article-title>Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor</article-title><source>Parkinsonism Relat Disord</source><year>2004</year><volume>10</volume><issue>6</issue><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2004.04.012</pub-id><?supplied-pmid 15261877?><pub-id pub-id-type="pmid">15261877</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Khan</surname><given-names>NL</given-names></name><name><surname>Pavese</surname><given-names>N</given-names></name><name><surname>Eunson</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>E</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Quinn</surname><given-names>NP</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Piccini</surname><given-names>PP</given-names></name></person-group><article-title>Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism</article-title><source>Brain</source><year>2004</year><volume>127</volume><issue>Pt 6</issue><fpage>1332</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1093/brain/awh150</pub-id><?supplied-pmid 15090472?><pub-id pub-id-type="pmid">15090472</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoli-Avella</surname><given-names>AM</given-names></name><name><surname>Giroud-Benitez</surname><given-names>JL</given-names></name><name><surname>Akyol</surname><given-names>A</given-names></name><name><surname>Barbosa</surname><given-names>E</given-names></name><name><surname>Schaap</surname><given-names>O</given-names></name><name><surname>van der Linde</surname><given-names>HC</given-names></name><name><surname>Martignoni</surname><given-names>E</given-names></name><name><surname>Lopiano</surname><given-names>L</given-names></name><name><surname>Lamberti</surname><given-names>P</given-names></name><name><surname>Fincati</surname><given-names>E</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Stocchi</surname><given-names>F</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Marini</surname><given-names>P</given-names></name><name><surname>Abbruzzese</surname><given-names>G</given-names></name><name><surname>Fabbrini</surname><given-names>G</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><name><surname>Dalla Libera</surname><given-names>A</given-names></name><name><surname>Trianni</surname><given-names>G</given-names></name><name><surname>Guidi</surname><given-names>M</given-names></name><name><surname>De Gaetano</surname><given-names>A</given-names></name><name><surname>Boff Maegawa</surname><given-names>G</given-names></name><name><surname>De Leo</surname><given-names>A</given-names></name><name><surname>Gallai</surname><given-names>V</given-names></name><name><surname>de Rosa</surname><given-names>G</given-names></name><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Italian Parkinson Genetics</surname><given-names>N</given-names></name></person-group><article-title>Novel parkin mutations detected in patients with early-onset Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2005</year><volume>20</volume><issue>4</issue><fpage>424</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1002/mds.20343</pub-id><?supplied-pmid 15584030?><pub-id pub-id-type="pmid">15584030</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardien</surname><given-names>S</given-names></name><name><surname>Keyser</surname><given-names>R</given-names></name><name><surname>Yako</surname><given-names>Y</given-names></name><name><surname>Lombard</surname><given-names>D</given-names></name><name><surname>Carr</surname><given-names>J</given-names></name></person-group><article-title>Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson&#x02019;s disease</article-title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><issue>2</issue><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2008.04.005</pub-id><?supplied-pmid 18514563?><pub-id pub-id-type="pmid">18514563</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Kissell</surname><given-names>DK</given-names></name><name><surname>Pauciulo</surname><given-names>MW</given-names></name><name><surname>Halter</surname><given-names>CA</given-names></name><name><surname>Rudolph</surname><given-names>A</given-names></name><name><surname>Pfeiffer</surname><given-names>RF</given-names></name><name><surname>Marder</surname><given-names>KS</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Nichols</surname><given-names>WC</given-names></name><collab>Parkinson Study Group PI</collab></person-group><article-title>Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations</article-title><source>Neurology</source><year>2009</year><volume>73</volume><issue>4</issue><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181af7a33</pub-id><?supplied-pmid 19636047?><pub-id pub-id-type="pmid">19636047</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Cognata</surname><given-names>V</given-names></name><name><surname>Iemmolo</surname><given-names>R</given-names></name><name><surname>D&#x02019;Agata</surname><given-names>V</given-names></name><name><surname>Scuderi</surname><given-names>S</given-names></name><name><surname>Drago</surname><given-names>F</given-names></name><name><surname>Zappia</surname><given-names>M</given-names></name><name><surname>Cavallaro</surname><given-names>S</given-names></name></person-group><article-title>Increasing the coding potential of genomes through alternative splicing: the case of PARK2 gene</article-title><source>Curr Genomics</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.2174/1389202915666140426003342</pub-id><?supplied-pmid 24955028?><pub-id pub-id-type="pmid">24955028</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitada</surname><given-names>T</given-names></name><name><surname>Asakawa</surname><given-names>S</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Matsumine</surname><given-names>H</given-names></name><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Yokochi</surname><given-names>M</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name></person-group><article-title>Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism</article-title><source>Nature</source><year>1998</year><volume>392</volume><issue>6676</issue><fpage>605</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/33416</pub-id><?supplied-pmid 9560156?><pub-id pub-id-type="pmid">9560156</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumine</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Shimoda-Matsubayashi</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>A</given-names></name><name><surname>Nakagawa-Hattori</surname><given-names>Y</given-names></name><name><surname>Yokochi</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Igarashi</surname><given-names>S</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Sanpei</surname><given-names>K</given-names></name><name><surname>Koike</surname><given-names>R</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Schaffer</surname><given-names>AA</given-names></name><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Kuzuhara</surname><given-names>S</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name></person-group><article-title>Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2&#x02013;27</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><issue>3</issue><fpage>588</fpage><lpage>596</lpage><?supplied-pmid 9042918?><pub-id pub-id-type="pmid">9042918</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>DC</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><article-title>An emerging role of PARK2 in cancer</article-title><source>J Mol Med (Berl)</source><year>2014</year><volume>92</volume><issue>1</issue><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/s00109-013-1107-0</pub-id><pub-id pub-id-type="pmid">24297497</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeuchi</surname><given-names>K</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Fujiwara</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Iwai</surname><given-names>A</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced parkin in human colorectal cancers</article-title><source>Int J Cancer</source><year>2009</year><volume>125</volume><issue>9</issue><fpage>2029</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1002/ijc.24565</pub-id><?supplied-pmid 19585504?><pub-id pub-id-type="pmid">19585504</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitada</surname><given-names>T</given-names></name><name><surname>Asakawa</surname><given-names>S</given-names></name><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name></person-group><article-title>Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene</article-title><source>Mamm Genome</source><year>2000</year><volume>11</volume><issue>6</issue><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1007/s003350010080</pub-id><?supplied-pmid 10818204?><pub-id pub-id-type="pmid">10818204</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humbert</surname><given-names>J</given-names></name><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Carrato</surname><given-names>C</given-names></name><name><surname>Mate</surname><given-names>JL</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Ariza</surname><given-names>A</given-names></name></person-group><article-title>Parkin and synphilin-1 isoform expression changes in Lewy body diseases</article-title><source>Neurobiol Dis</source><year>2007</year><volume>26</volume><issue>3</issue><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2007.03.007</pub-id><?supplied-pmid 17467279?><pub-id pub-id-type="pmid">17467279</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>JM</given-names></name><name><surname>Lim</surname><given-names>KL</given-names></name><name><surname>Fook-Chong</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>WP</given-names></name><name><surname>Paterson</surname><given-names>MC</given-names></name><name><surname>Chandran</surname><given-names>VR</given-names></name><name><surname>Yew</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Yuen</surname><given-names>Y</given-names></name><name><surname>Pavanni</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>MC</given-names></name><name><surname>Puvan</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Differential expression of splice variant and wild-type parkin in sporadic Parkinson&#x02019;s disease</article-title><source>Neurogenetics</source><year>2005</year><volume>6</volume><issue>4</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s10048-005-0001-5</pub-id><?supplied-pmid 16086186?><pub-id pub-id-type="pmid">16086186</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagata</surname><given-names>V</given-names></name><name><surname>Cavallaro</surname><given-names>S</given-names></name></person-group><article-title>Parkin transcript variants in rat and human brain</article-title><source>Neurochem Res</source><year>2004</year><volume>29</volume><issue>9</issue><fpage>1715</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1023/B:NERE.0000035807.25370.5e</pub-id><?supplied-pmid 15453267?><pub-id pub-id-type="pmid">15453267</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunada</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>F</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name></person-group><article-title>Differential expression of the parkin gene in the human brain and peripheral leukocytes</article-title><source>Neurosci Lett</source><year>1998</year><volume>254</volume><issue>3</issue><fpage>180</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(98)00697-1</pub-id><?supplied-pmid 10214987?><pub-id pub-id-type="pmid">10214987</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solano</surname><given-names>SM</given-names></name><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Augood</surname><given-names>SJ</given-names></name><name><surname>Young</surname><given-names>AB</given-names></name><name><surname>Penney</surname><given-names>JB</given-names><suffix>Jr</suffix></name></person-group><article-title>Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>2000</year><volume>47</volume><issue>2</issue><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(200002)47:2&#x0003c;201::AID-ANA10&#x0003e;3.0.CO;2-F</pub-id><?supplied-pmid 10665491?><pub-id pub-id-type="pmid">10665491</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasap</surname><given-names>M</given-names></name><name><surname>Akpinar</surname><given-names>G</given-names></name><name><surname>Sazci</surname><given-names>A</given-names></name><name><surname>Idrisoglu</surname><given-names>HA</given-names></name><name><surname>Vahaboglu</surname><given-names>H</given-names></name></person-group><article-title>Evidence for the presence of full-length PARK2 mRNA and parkin protein in human blood</article-title><source>Neurosci Lett</source><year>2009</year><volume>460</volume><issue>3</issue><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.05.079</pub-id><?supplied-pmid 19501131?><pub-id pub-id-type="pmid">19501131</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlyk</surname><given-names>AC</given-names></name><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Sampathu</surname><given-names>DM</given-names></name><name><surname>Perez</surname><given-names>FA</given-names></name><name><surname>Lim</surname><given-names>KL</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><issue>48</issue><fpage>48120</fpage><lpage>48128</lpage><pub-id pub-id-type="doi">10.1074/jbc.M306889200</pub-id><?supplied-pmid 12972409?><pub-id pub-id-type="pmid">12972409</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>JM</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Stachowiak</surname><given-names>MK</given-names></name><name><surname>Torres</surname><given-names>G</given-names></name></person-group><article-title>Identification and distribution of Parkin in rat brain</article-title><source>Neuroreport</source><year>1999</year><volume>10</volume><issue>16</issue><fpage>3393</fpage><lpage>3397</lpage><pub-id pub-id-type="doi">10.1097/00001756-199911080-00025</pub-id><?supplied-pmid 10599851?><pub-id pub-id-type="pmid">10599851</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stichel</surname><given-names>CC</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Kuhn</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>XR</given-names></name><name><surname>Engels</surname><given-names>P</given-names></name><name><surname>Ullmer</surname><given-names>C</given-names></name><name><surname>Lubbert</surname><given-names>H</given-names></name></person-group><article-title>Parkin expression in the adult mouse brain</article-title><source>Eur J Neurosci</source><year>2000</year><volume>12</volume><issue>12</issue><fpage>4181</fpage><lpage>4194</lpage><?supplied-pmid 11122330?><pub-id pub-id-type="pmid">11122330</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>WJ</given-names></name><name><surname>Abbas</surname><given-names>N</given-names></name><name><surname>Lagunes</surname><given-names>MZ</given-names></name><name><surname>Parent</surname><given-names>A</given-names></name><name><surname>Pradier</surname><given-names>L</given-names></name><name><surname>Bohme</surname><given-names>GA</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Hirsch</surname><given-names>EC</given-names></name><name><surname>Raisman-Vozari</surname><given-names>R</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group><article-title>Cloning of rat parkin cDNA and distribution of parkin in rat brain</article-title><source>J Neurochem</source><year>2000</year><volume>74</volume><issue>4</issue><fpage>1773</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0741773.x</pub-id><?supplied-pmid 10737637?><pub-id pub-id-type="pmid">10737637</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>DP</given-names></name><name><surname>Dy</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Kiehl</surname><given-names>TR</given-names></name><name><surname>Pulst</surname><given-names>SM</given-names></name></person-group><article-title>Differential expression and tissue distribution of parkin isoforms during mouse development</article-title><source>Brain Res Dev Brain Res</source><year>2001</year><volume>130</volume><issue>2</issue><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/S0165-3806(01)00234-6</pub-id><?supplied-pmid 11675120?><pub-id pub-id-type="pmid">11675120</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Agata</surname><given-names>V</given-names></name><name><surname>Grimaldi</surname><given-names>M</given-names></name><name><surname>Pascale</surname><given-names>A</given-names></name><name><surname>Cavallaro</surname><given-names>S</given-names></name></person-group><article-title>Regional and cellular expression of the parkin gene in the rat cerebral cortex</article-title><source>Eur J Neurosci</source><year>2000</year><volume>12</volume><issue>10</issue><fpage>3583</fpage><lpage>3588</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.2000.00244.x</pub-id><?supplied-pmid 11029628?><pub-id pub-id-type="pmid">11029628</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogson</surname><given-names>JH</given-names></name><name><surname>Ivatt</surname><given-names>RM</given-names></name><name><surname>Whitworth</surname><given-names>AJ</given-names></name></person-group><article-title>Molecular mechanisms of PINK1-related neurodegeneration</article-title><source>Curr Neurol Neurosci Rep</source><year>2011</year><volume>11</volume><issue>3</issue><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s11910-011-0187-x</pub-id><?supplied-pmid 21331528?><pub-id pub-id-type="pmid">21331528</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuytemans</surname><given-names>K</given-names></name><name><surname>Theuns</surname><given-names>J</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update</article-title><source>Hum Mutat</source><year>2010</year><volume>31</volume><issue>7</issue><fpage>763</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1002/humu.21277</pub-id><?supplied-pmid 20506312?><pub-id pub-id-type="pmid">20506312</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marongiu</surname><given-names>R</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Ialongo</surname><given-names>T</given-names></name><name><surname>Ceccarini</surname><given-names>C</given-names></name><name><surname>Scarciolla</surname><given-names>O</given-names></name><name><surname>Capalbo</surname><given-names>A</given-names></name><name><surname>Benti</surname><given-names>R</given-names></name><name><surname>Pezzoli</surname><given-names>G</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Goldwurm</surname><given-names>S</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name></person-group><article-title>Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum</article-title><source>Hum Mutat</source><year>2007</year><volume>28</volume><issue>1</issue><fpage>98</fpage><pub-id pub-id-type="doi">10.1002/humu.9472</pub-id><?supplied-pmid 17154281?><pub-id pub-id-type="pmid">17154281</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samaranch</surname><given-names>L</given-names></name><name><surname>Lorenzo-Betancor</surname><given-names>O</given-names></name><name><surname>Arbelo</surname><given-names>JM</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Lorenzo</surname><given-names>E</given-names></name><name><surname>Irigoyen</surname><given-names>J</given-names></name><name><surname>Pastor</surname><given-names>MA</given-names></name><name><surname>Marrero</surname><given-names>C</given-names></name><name><surname>Isla</surname><given-names>C</given-names></name><name><surname>Herrera-Henriquez</surname><given-names>J</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name></person-group><article-title>PINK1-linked parkinsonism is associated with Lewy body pathology</article-title><source>Brain</source><year>2010</year><volume>133</volume><issue>Pt 4</issue><fpage>1128</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1093/brain/awq051</pub-id><?supplied-pmid 20356854?><pub-id pub-id-type="pmid">20356854</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Abou-Sleiman</surname><given-names>PM</given-names></name><name><surname>Caputo</surname><given-names>V</given-names></name><name><surname>Muqit</surname><given-names>MM</given-names></name><name><surname>Harvey</surname><given-names>K</given-names></name><name><surname>Gispert</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Del Turco</surname><given-names>D</given-names></name><name><surname>Bentivoglio</surname><given-names>AR</given-names></name><name><surname>Healy</surname><given-names>DG</given-names></name><name><surname>Albanese</surname><given-names>A</given-names></name><name><surname>Nussbaum</surname><given-names>R</given-names></name><name><surname>Gonzalez-Maldonado</surname><given-names>R</given-names></name><name><surname>Deller</surname><given-names>T</given-names></name><name><surname>Salvi</surname><given-names>S</given-names></name><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>Gilks</surname><given-names>WP</given-names></name><name><surname>Latchman</surname><given-names>DS</given-names></name><name><surname>Harvey</surname><given-names>RJ</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>Hereditary early-onset Parkinson&#x02019;s disease caused by mutations in PINK1</article-title><source>Science</source><year>2004</year><volume>304</volume><issue>5674</issue><fpage>1158</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1126/science.1096284</pub-id><?supplied-pmid 15087508?><pub-id pub-id-type="pmid">15087508</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Caputo</surname><given-names>V</given-names></name><name><surname>Bellacchio</surname><given-names>E</given-names></name><name><surname>Atorino</surname><given-names>L</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><issue>22</issue><fpage>3477</fpage><lpage>3492</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi377</pub-id><?supplied-pmid 16207731?><pub-id pub-id-type="pmid">16207731</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beilina</surname><given-names>A</given-names></name><name><surname>Van Der Brug</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Kesavapany</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Petsko</surname><given-names>GA</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name></person-group><article-title>Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>16</issue><fpage>5703</fpage><lpage>5708</lpage><pub-id pub-id-type="doi">10.1073/pnas.0500617102</pub-id><?supplied-pmid 15824318?><pub-id pub-id-type="pmid">15824318</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d&#x02019;Amora</surname><given-names>M</given-names></name><name><surname>Angelini</surname><given-names>C</given-names></name><name><surname>Marcoli</surname><given-names>M</given-names></name><name><surname>Cervetto</surname><given-names>C</given-names></name><name><surname>Kitada</surname><given-names>T</given-names></name><name><surname>Vallarino</surname><given-names>M</given-names></name></person-group><article-title>Expression of PINK1 in the brain, eye and ear of mouse during embryonic development</article-title><source>J Chem Neuroanat</source><year>2011</year><volume>41</volume><issue>2</issue><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2010.11.004</pub-id><?supplied-pmid 21126574?><pub-id pub-id-type="pmid">21126574</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Kang</surname><given-names>UJ</given-names></name></person-group><article-title>Characterization of PINK1 processing, stability, and subcellular localization</article-title><source>J Neurochem</source><year>2008</year><volume>106</volume><issue>1</issue><fpage>464</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05398.x</pub-id><?supplied-pmid 18397367?><pub-id pub-id-type="pmid">18397367</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deas</surname><given-names>E</given-names></name><name><surname>Plun-Favreau</surname><given-names>H</given-names></name><name><surname>Gandhi</surname><given-names>S</given-names></name><name><surname>Desmond</surname><given-names>H</given-names></name><name><surname>Kjaer</surname><given-names>S</given-names></name><name><surname>Loh</surname><given-names>SH</given-names></name><name><surname>Renton</surname><given-names>AE</given-names></name><name><surname>Harvey</surname><given-names>RJ</given-names></name><name><surname>Whitworth</surname><given-names>AJ</given-names></name><name><surname>Martins</surname><given-names>LM</given-names></name><name><surname>Abramov</surname><given-names>AY</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>PINK1 cleavage at position A103 by the mitochondrial protease PARL</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><issue>5</issue><fpage>867</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq526</pub-id><?supplied-pmid 21138942?><pub-id pub-id-type="pmid">21138942</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockhart</surname><given-names>PJ</given-names></name><name><surname>Lincoln</surname><given-names>S</given-names></name><name><surname>Hulihan</surname><given-names>M</given-names></name><name><surname>Kachergus</surname><given-names>J</given-names></name><name><surname>Wilkes</surname><given-names>K</given-names></name><name><surname>Bisceglio</surname><given-names>G</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name></person-group><article-title>DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><issue>3</issue><fpage>e22</fpage><pub-id pub-id-type="doi">10.1136/jmg.2003.011106</pub-id><?supplied-pmid 14985393?><pub-id pub-id-type="pmid">14985393</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DJ</given-names></name><name><surname>West</surname><given-names>AB</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name></person-group><article-title>Molecular pathophysiology of Parkinson&#x02019;s disease</article-title><source>Annu Rev Neurosci</source><year>2005</year><volume>28</volume><fpage>57</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.28.061604.135718</pub-id><?supplied-pmid 16022590?><pub-id pub-id-type="pmid">16022590</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Krieger</surname><given-names>E</given-names></name><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Oostra</surname><given-names>B</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name></person-group><article-title>DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism</article-title><source>Neurol Sci</source><year>2003</year><volume>24</volume><issue>3</issue><fpage>159</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s10072-003-0108-0</pub-id><?supplied-pmid 14598065?><pub-id pub-id-type="pmid">14598065</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Dekker</surname><given-names>MC</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Galjaard</surname><given-names>RJ</given-names></name><name><surname>Houwing-Duistermaat</surname><given-names>JJ</given-names></name><name><surname>Snijders</surname><given-names>PJ</given-names></name><name><surname>Testers</surname><given-names>L</given-names></name><name><surname>Breedveld</surname><given-names>GJ</given-names></name><name><surname>Horstink</surname><given-names>M</given-names></name><name><surname>Sandkuijl</surname><given-names>LA</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name></person-group><article-title>Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36</article-title><source>Am J Hum Genet</source><year>2001</year><volume>69</volume><issue>3</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1086/322996</pub-id><?supplied-pmid 11462174?><pub-id pub-id-type="pmid">11462174</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>O</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group><article-title>What genetics tells us about the causes and mechanisms of Parkinson&#x02019;s disease</article-title><source>Physiol Rev</source><year>2011</year><volume>91</volume><issue>4</issue><fpage>1161</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1152/physrev.00022.2010</pub-id><?supplied-pmid 22013209?><pub-id pub-id-type="pmid">22013209</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantino</surname><given-names>P</given-names></name><name><surname>Civitelli</surname><given-names>D</given-names></name><name><surname>Annesi</surname><given-names>F</given-names></name><name><surname>De Marco</surname><given-names>EV</given-names></name><name><surname>Rocca</surname><given-names>FE</given-names></name><name><surname>Pugliese</surname><given-names>P</given-names></name><name><surname>Nicoletti</surname><given-names>G</given-names></name><name><surname>Carrideo</surname><given-names>S</given-names></name><name><surname>Provenzano</surname><given-names>G</given-names></name><name><surname>Annesi</surname><given-names>G</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name></person-group><article-title>Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism</article-title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><issue>4</issue><fpage>324</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2008.07.001</pub-id><?supplied-pmid 18722801?><pub-id pub-id-type="pmid">18722801</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedrich</surname><given-names>K</given-names></name><name><surname>Djarmati</surname><given-names>A</given-names></name><name><surname>Schafer</surname><given-names>N</given-names></name><name><surname>Hering</surname><given-names>R</given-names></name><name><surname>Wellenbrock</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>PH</given-names></name><name><surname>Hilker</surname><given-names>R</given-names></name><name><surname>Vieregge</surname><given-names>P</given-names></name><name><surname>Ozelius</surname><given-names>LJ</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Schwinger</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Noth</surname><given-names>J</given-names></name><name><surname>Bressman</surname><given-names>SB</given-names></name><name><surname>Pramstaller</surname><given-names>PP</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name></person-group><article-title>DJ-1 (PARK7) mutations are less frequent than parkin (PARK2) mutations in early-onset Parkinson disease</article-title><source>Neurology</source><year>2004</year><volume>62</volume><issue>3</issue><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000113022.51739.88</pub-id><?supplied-pmid 14872018?><pub-id pub-id-type="pmid">14872018</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lev</surname><given-names>N</given-names></name><name><surname>Roncevic</surname><given-names>D</given-names></name><name><surname>Ickowicz</surname><given-names>D</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><name><surname>Offen</surname><given-names>D</given-names></name></person-group><article-title>Role of DJ-1 in Parkinson&#x02019;s disease</article-title><source>J Mol Neurosci</source><year>2006</year><volume>29</volume><issue>3</issue><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1385/JMN:29:3:215</pub-id><?supplied-pmid 17085780?><pub-id pub-id-type="pmid">17085780</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariga</surname><given-names>H</given-names></name><name><surname>Takahashi-Niki</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>I</given-names></name><name><surname>Maita</surname><given-names>H</given-names></name><name><surname>Niki</surname><given-names>T</given-names></name><name><surname>Iguchi-Ariga</surname><given-names>SM</given-names></name></person-group><article-title>Neuroprotective function of DJ-1 in Parkinson&#x02019;s disease</article-title><source>Oxid Med Cell Longev</source><year>2013</year><volume>2013</volume><fpage>683920</fpage><pub-id pub-id-type="doi">10.1155/2013/683920</pub-id><?supplied-pmid 23766857?><pub-id pub-id-type="pmid">23766857</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Woldman</surname><given-names>I</given-names></name><name><surname>Pifl</surname><given-names>C</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Geula</surname><given-names>C</given-names></name><name><surname>Yankner</surname><given-names>BA</given-names></name></person-group><article-title>The Parkinson&#x02019;s disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><issue>9</issue><fpage>1231</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi134</pub-id><?supplied-pmid 15790595?><pub-id pub-id-type="pmid">15790595</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandopadhyay</surname><given-names>R</given-names></name><name><surname>Kingsbury</surname><given-names>AE</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Reid</surname><given-names>AR</given-names></name><name><surname>Evans</surname><given-names>IM</given-names></name><name><surname>Hope</surname><given-names>AD</given-names></name><name><surname>Pittman</surname><given-names>AM</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Canet-Aviles</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>McLendon</surname><given-names>C</given-names></name><name><surname>Strand</surname><given-names>C</given-names></name><name><surname>Leonard</surname><given-names>AJ</given-names></name><name><surname>Abou-Sleiman</surname><given-names>PM</given-names></name><name><surname>Healy</surname><given-names>DG</given-names></name><name><surname>Ariga</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson&#x02019;s disease</article-title><source>Brain</source><year>2004</year><volume>127</volume><issue>Pt 2</issue><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1093/brain/awh054</pub-id><?supplied-pmid 14662519?><pub-id pub-id-type="pmid">14662519</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besong Agbo</surname><given-names>D</given-names></name><name><surname>Klafki</surname><given-names>H</given-names></name><name><surname>Poschmann</surname><given-names>G</given-names></name><name><surname>Seyfarth</surname><given-names>K</given-names></name><name><surname>Genius</surname><given-names>J</given-names></name><name><surname>Janssen</surname><given-names>C</given-names></name><name><surname>Stuhler</surname><given-names>K</given-names></name><name><surname>Wurst</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Klingenspor</surname><given-names>M</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name></person-group><article-title>Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples</article-title><source>Anal Biochem</source><year>2013</year><volume>443</volume><issue>2</issue><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2013.09.013</pub-id><?supplied-pmid 24055619?><pub-id pub-id-type="pmid">24055619</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaran</surname><given-names>R</given-names></name><name><surname>Kingsbury</surname><given-names>A</given-names></name><name><surname>Coulter</surname><given-names>I</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Bandopadhyay</surname><given-names>R</given-names></name></person-group><article-title>DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders</article-title><source>Neurobiol Dis</source><year>2007</year><volume>28</volume><issue>1</issue><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2007.07.012</pub-id><?supplied-pmid 17719794?><pub-id pub-id-type="pmid">17719794</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaran</surname><given-names>R</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>Luk</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Renton</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Bandopadhyay</surname><given-names>R</given-names></name></person-group><article-title>Differential DJ-1 gene expression in Parkinson&#x02019;s disease</article-title><source>Neurobiol Dis</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.08.011</pub-id><?supplied-pmid 19716892?><pub-id pub-id-type="pmid">19716892</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Cook</surname><given-names>TJ</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Hu</surname><given-names>SC</given-names></name><name><surname>Cain</surname><given-names>KC</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Edgar</surname><given-names>JS</given-names></name><name><surname>Goodlett</surname><given-names>DR</given-names></name><name><surname>Racette</surname><given-names>BA</given-names></name><name><surname>Checkoway</surname><given-names>H</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease</article-title><source>Sci Rep</source><year>2012</year><volume>2</volume><fpage>954</fpage><?supplied-pmid 23233873?><pub-id pub-id-type="pmid">23233873</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Geula</surname><given-names>C</given-names></name><name><surname>Porter</surname><given-names>DR</given-names></name><name><surname>Pothos</surname><given-names>EN</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><issue>30</issue><fpage>20940</fpage><lpage>20948</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601935200</pub-id><?supplied-pmid 16731528?><pub-id pub-id-type="pmid">16731528</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilarino-Guell</surname><given-names>C</given-names></name><name><surname>Soto</surname><given-names>AI</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>Ben Yahmed</surname><given-names>S</given-names></name><name><surname>Kefi</surname><given-names>M</given-names></name><name><surname>Heckman</surname><given-names>MG</given-names></name><name><surname>Hulihan</surname><given-names>MM</given-names></name><name><surname>Chai</surname><given-names>H</given-names></name><name><surname>Diehl</surname><given-names>NN</given-names></name><name><surname>Amouri</surname><given-names>R</given-names></name><name><surname>Rajput</surname><given-names>A</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Gibson</surname><given-names>RA</given-names></name><name><surname>Hentati</surname><given-names>F</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name></person-group><article-title>ATP13A2 variability in Parkinson disease</article-title><source>Hum Mutat</source><year>2009</year><volume>30</volume><issue>3</issue><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1002/humu.20877</pub-id><?supplied-pmid 19085912?><pub-id pub-id-type="pmid">19085912</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KE</given-names></name><name><surname>Cottle</surname><given-names>L</given-names></name><name><surname>Gysbers</surname><given-names>AM</given-names></name><name><surname>Cooper</surname><given-names>AA</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name></person-group><article-title>ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies</article-title><source>Acta Neuropathol Commun</source><year>2013</year><volume>1</volume><issue>1</issue><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-1-11</pub-id><?supplied-pmid 24252509?><pub-id pub-id-type="pmid">24252509</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ugolino</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Kubisch</surname><given-names>C</given-names></name><name><surname>Monteiro</surname><given-names>MJ</given-names></name></person-group><article-title>Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><issue>18</issue><fpage>3565</fpage><lpage>3577</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr274</pub-id><?supplied-pmid 21665991?><pub-id pub-id-type="pmid">21665991</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>CS</given-names></name><name><surname>Lai</surname><given-names>SC</given-names></name><name><surname>Wu</surname><given-names>RM</given-names></name><name><surname>Weng</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>RS</given-names></name><name><surname>Chang</surname><given-names>HC</given-names></name><name><surname>Wu-Chou</surname><given-names>YH</given-names></name><name><surname>Yeh</surname><given-names>TH</given-names></name></person-group><article-title>PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson&#x02019;s disease</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2012</year><volume>159B</volume><issue>2</issue><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.32012</pub-id><?supplied-pmid 22213678?><pub-id pub-id-type="pmid">22213678</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fonzo</surname><given-names>A</given-names></name><name><surname>Dekker</surname><given-names>MC</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Baruzzi</surname><given-names>A</given-names></name><name><surname>Yonova</surname><given-names>EH</given-names></name><name><surname>Correia Guedes</surname><given-names>L</given-names></name><name><surname>Szczerbinska</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Dubbel-Hulsman</surname><given-names>LO</given-names></name><name><surname>Wouters</surname><given-names>CH</given-names></name><name><surname>de Graaff</surname><given-names>E</given-names></name><name><surname>Oyen</surname><given-names>WJ</given-names></name><name><surname>Simons</surname><given-names>EJ</given-names></name><name><surname>Breedveld</surname><given-names>GJ</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Horstink</surname><given-names>MW</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name></person-group><article-title>FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome</article-title><source>Neurology</source><year>2009</year><volume>72</volume><issue>3</issue><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000338144.10967.2b</pub-id><?supplied-pmid 19038853?><pub-id pub-id-type="pmid">19038853</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name></person-group><article-title>F-box only protein 7 gene in parkinsonian-pyramidal disease</article-title><source>JAMA Neurol</source><year>2013</year><volume>70</volume><issue>1</issue><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2013.572</pub-id><?supplied-pmid 23318512?><pub-id pub-id-type="pmid">23318512</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><mixed-citation publication-type="other">Gomez-Garre P, Jesus S, Carrillo F, Caceres-Redondo MT, Huertas-Fernandez I, Bernal-Bernal I, Bonilla-Toribio M, Vargas-Gonzalez L, Carballo M, Mir P (2014) Systematic mutational analysis of FBXO7 in a Parkinson&#x02019;s disease population from southern Spain. Neurobiol Aging 35(3):727. e5&#x02013;7. doi:10.1016/j.neurobiolaging.2013.09.011</mixed-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilyin</surname><given-names>GP</given-names></name><name><surname>Rialland</surname><given-names>M</given-names></name><name><surname>Pigeon</surname><given-names>C</given-names></name><name><surname>Guguen-Guillouzo</surname><given-names>C</given-names></name></person-group><article-title>cDNA cloning and expression analysis of new members of the mammalian F-box protein family</article-title><source>Genomics</source><year>2000</year><volume>67</volume><issue>1</issue><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1006/geno.2000.6211</pub-id><?supplied-pmid 10945468?><pub-id pub-id-type="pmid">10945468</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>De Graaff</surname><given-names>E</given-names></name><name><surname>Breedveld</surname><given-names>GJ</given-names></name><name><surname>Loda</surname><given-names>A</given-names></name><name><surname>Severijnen</surname><given-names>LA</given-names></name><name><surname>Wouters</surname><given-names>CH</given-names></name><name><surname>Verheijen</surname><given-names>FW</given-names></name><name><surname>Dekker</surname><given-names>MC</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Willemsen</surname><given-names>R</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name></person-group><article-title>Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15)</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>2</issue><fpage>e16983</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0016983</pub-id><?supplied-pmid 21347293?><pub-id pub-id-type="pmid">21347293</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>D</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name></person-group><article-title>Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><issue>18</issue><fpage>10347</fpage><lpage>10352</lpage><pub-id pub-id-type="doi">10.1073/pnas.1831949100</pub-id><?supplied-pmid 12928496?><pub-id pub-id-type="pmid">12928496</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herzfeld</surname><given-names>T</given-names></name><name><surname>Nolte</surname><given-names>D</given-names></name><name><surname>Grznarova</surname><given-names>M</given-names></name><name><surname>Hofmann</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name></person-group><article-title>X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><issue>5</issue><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds499</pub-id><?supplied-pmid 23184149?><pub-id pub-id-type="pmid">23184149</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korvatska</surname><given-names>O</given-names></name><name><surname>Strand</surname><given-names>NS</given-names></name><name><surname>Berndt</surname><given-names>JD</given-names></name><name><surname>Strovas</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>DH</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Kiianitsa</surname><given-names>K</given-names></name><name><surname>Mata</surname><given-names>IF</given-names></name><name><surname>Karakoc</surname><given-names>E</given-names></name><name><surname>Greenup</surname><given-names>JL</given-names></name><name><surname>Bonkowski</surname><given-names>E</given-names></name><name><surname>Chuang</surname><given-names>J</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Kraemer</surname><given-names>BC</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Raskind</surname><given-names>WH</given-names></name></person-group><article-title>Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS)</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><issue>16</issue><fpage>3259</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt180</pub-id><?supplied-pmid 23595882?><pub-id pub-id-type="pmid">23595882</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myhre</surname><given-names>R</given-names></name><name><surname>Klungland</surname><given-names>H</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name></person-group><article-title>Genetic association study of synphilin-1 in idiopathic Parkinson&#x02019;s disease</article-title><source>BMC Med Genet</source><year>2008</year><volume>9</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1471-2350-9-19</pub-id><?supplied-pmid 18366718?><pub-id pub-id-type="pmid">18366718</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyser</surname><given-names>RJ</given-names></name><name><surname>Oppon</surname><given-names>E</given-names></name><name><surname>Carr</surname><given-names>JA</given-names></name><name><surname>Bardien</surname><given-names>S</given-names></name></person-group><article-title>Identification of Parkinson&#x02019;s disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson&#x02019;s disease patients</article-title><source>J Neural Transm</source><year>2011</year><volume>118</volume><issue>6</issue><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1007/s00702-011-0591-z</pub-id><?supplied-pmid 21344240?><pub-id pub-id-type="pmid">21344240</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>FP</given-names></name><name><surname>Holzmann</surname><given-names>C</given-names></name><name><surname>Strauss</surname><given-names>KM</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Eberhardt</surname><given-names>O</given-names></name><name><surname>Gerhardt</surname><given-names>E</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Kachergus</surname><given-names>J</given-names></name><name><surname>Engelender</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Berger</surname><given-names>K</given-names></name><name><surname>Schols</surname><given-names>L</given-names></name><name><surname>Schulz</surname><given-names>JB</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><name><surname>Kruger</surname><given-names>R</given-names></name></person-group><article-title>Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson&#x02019;s disease</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><issue>11</issue><fpage>1223</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg134</pub-id><?supplied-pmid 12761037?><pub-id pub-id-type="pmid">12761037</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyal</surname><given-names>A</given-names></name><name><surname>Szargel</surname><given-names>R</given-names></name><name><surname>Avraham</surname><given-names>E</given-names></name><name><surname>Liani</surname><given-names>E</given-names></name><name><surname>Haskin</surname><given-names>J</given-names></name><name><surname>Rott</surname><given-names>R</given-names></name><name><surname>Engelender</surname><given-names>S</given-names></name></person-group><article-title>Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><issue>15</issue><fpage>5917</fpage><lpage>5922</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509707103</pub-id><?supplied-pmid 16595633?><pub-id pub-id-type="pmid">16595633</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyal</surname><given-names>A</given-names></name><name><surname>Engelender</surname><given-names>S</given-names></name></person-group><article-title>Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson&#x02019;s disease</article-title><source>Cell Cycle</source><year>2006</year><volume>5</volume><issue>18</issue><fpage>2082</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.4161/cc.5.18.3209</pub-id><?supplied-pmid 16969096?><pub-id pub-id-type="pmid">16969096</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szargel</surname><given-names>R</given-names></name><name><surname>Rott</surname><given-names>R</given-names></name><name><surname>Engelender</surname><given-names>S</given-names></name></person-group><article-title>Synphilin-1 isoforms in Parkinson&#x02019;s disease: regulation by phosphorylation and ubiquitylation</article-title><source>Cell Mol Life Sci</source><year>2008</year><volume>65</volume><issue>1</issue><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00018-007-7343-0</pub-id><?supplied-pmid 17982729?><pub-id pub-id-type="pmid">17982729</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>P</given-names></name><name><surname>Ayton</surname><given-names>S</given-names></name><name><surname>Finkelstein</surname><given-names>DI</given-names></name><name><surname>Adlard</surname><given-names>PA</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Bush</surname><given-names>AI</given-names></name></person-group><article-title>Tau protein: relevance to Parkinson&#x02019;s disease</article-title><source>Int J Biochem Cell Biol</source><year>2010</year><volume>42</volume><issue>11</issue><fpage>1775</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2010.07.016</pub-id><?supplied-pmid 20678581?><pub-id pub-id-type="pmid">20678581</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spatola</surname><given-names>M</given-names></name><name><surname>Wider</surname><given-names>C</given-names></name></person-group><article-title>Genetics of Parkinson&#x02019;s disease: the yield</article-title><source>Parkinsonism Relat Disord</source><year>2014</year><volume>20</volume><issue>1</issue><fpage>S35</fpage><lpage>S38</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(13)70011-7</pub-id><?supplied-pmid 24262184?><pub-id pub-id-type="pmid">24262184</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svobodova</surname><given-names>E</given-names></name><name><surname>Mrazova</surname><given-names>L</given-names></name><name><surname>Luksan</surname><given-names>O</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Stolnaya</surname><given-names>L</given-names></name><name><surname>Minks</surname><given-names>J</given-names></name><name><surname>Eberova</surname><given-names>J</given-names></name><name><surname>Dvorakova</surname><given-names>L</given-names></name><name><surname>Jirsa</surname><given-names>M</given-names></name><name><surname>Hrebicek</surname><given-names>M</given-names></name></person-group><article-title>Glucocerebrosidase gene has an alternative upstream promoter, which has features and expression characteristic of housekeeping genes</article-title><source>Blood Cells Mol Dis</source><year>2011</year><volume>46</volume><issue>3</issue><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2010.12.011</pub-id><?supplied-pmid 21256059?><pub-id pub-id-type="pmid">21256059</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubauskiene</surname><given-names>E</given-names></name><name><surname>Janaviciute</surname><given-names>V</given-names></name><name><surname>Peciuliene</surname><given-names>I</given-names></name><name><surname>Soderkvist</surname><given-names>P</given-names></name><name><surname>Kanopka</surname><given-names>A</given-names></name></person-group><article-title>G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease</article-title><source>FEBS Lett</source><year>2012</year><volume>586</volume><issue>20</issue><fpage>3698</fpage><lpage>3704</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2012.08.028</pub-id><?supplied-pmid 22974659?><pub-id pub-id-type="pmid">22974659</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>T</given-names></name></person-group><article-title>Monoamine oxidase-B inhibitors in the treatment of Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><issue>2</issue><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00100-7</pub-id><?supplied-pmid 10867219?><pub-id pub-id-type="pmid">10867219</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>G</given-names></name></person-group><article-title>Neuroprotection by selegiline and other MAO inhibitors</article-title><source>J Neural Transm Suppl</source><year>1998</year><volume>52</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/978-3-7091-6499-0_12</pub-id><?supplied-pmid 9564613?><pub-id pub-id-type="pmid">9564613</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>SL</given-names></name><name><surname>Kapadi</surname><given-names>AL</given-names></name><name><surname>Ramsden</surname><given-names>DB</given-names></name><name><surname>Williams</surname><given-names>AC</given-names></name></person-group><article-title>An allelic association study of monoamine oxidase B in Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>1995</year><volume>37</volume><issue>3</issue><fpage>403</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/ana.410370318</pub-id><?supplied-pmid 7695241?><pub-id pub-id-type="pmid">7695241</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurth</surname><given-names>JH</given-names></name><name><surname>Kurth</surname><given-names>MC</given-names></name><name><surname>Poduslo</surname><given-names>SE</given-names></name><name><surname>Schwankhaus</surname><given-names>JD</given-names></name></person-group><article-title>Association of a monoamine oxidase B allele with Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>1993</year><volume>33</volume><issue>4</issue><fpage>368</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1002/ana.410330406</pub-id><?supplied-pmid 8489207?><pub-id pub-id-type="pmid">8489207</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobell</surname><given-names>JL</given-names></name><name><surname>Lind</surname><given-names>TJ</given-names></name><name><surname>Hebrink</surname><given-names>DD</given-names></name><name><surname>Heston</surname><given-names>LL</given-names></name><name><surname>Sommer</surname><given-names>SS</given-names></name></person-group><article-title>Screening the monoamine oxidase B gene in 100 male patients with schizophrenia: a cluster of polymorphisms in African-Americans but lack of functionally significant sequence changes</article-title><source>Am J Med Genet</source><year>1997</year><volume>74</volume><issue>1</issue><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970221)74:1&#x0003c;44::AID-AJMG10&#x0003e;3.0.CO;2-R</pub-id><?supplied-pmid 9034005?><pub-id pub-id-type="pmid">9034005</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shehadeh</surname><given-names>LA</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Guevara</surname><given-names>A</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><name><surname>Vance</surname><given-names>J</given-names></name><name><surname>Papapetropoulos</surname><given-names>S</given-names></name></person-group><article-title>SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson&#x02019;s disease</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>2</issue><fpage>e9104</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009104</pub-id><?supplied-pmid 20161708?><pub-id pub-id-type="pmid">20161708</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamper</surname><given-names>C</given-names></name><name><surname>Siegel</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>WS</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Stephan</surname><given-names>DA</given-names></name><name><surname>Shill</surname><given-names>H</given-names></name><name><surname>Connor</surname><given-names>D</given-names></name><name><surname>Caviness</surname><given-names>JN</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Dunckley</surname><given-names>T</given-names></name></person-group><article-title>Neuronal gene expression correlates of Parkinson&#x02019;s disease with dementia</article-title><source>Mov Disord</source><year>2008</year><volume>23</volume><issue>11</issue><fpage>1588</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1002/mds.22184</pub-id><?supplied-pmid 18649390?><pub-id pub-id-type="pmid">18649390</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soreq</surname><given-names>L</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Israel</surname><given-names>Z</given-names></name><name><surname>Soreq</surname><given-names>H</given-names></name></person-group><article-title>Exon arrays reveal alternative splicing aberrations in Parkinson&#x02019;s disease leukocytes</article-title><source>Neurodegener Dis</source><year>2012</year><volume>10</volume><issue>1&#x02013;4</issue><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1159/000332598</pub-id><?supplied-pmid 22156489?><pub-id pub-id-type="pmid">22156489</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soreq</surname><given-names>L</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Israel</surname><given-names>Z</given-names></name><name><surname>Soreq</surname><given-names>H</given-names></name></person-group><article-title>Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson&#x02019;s patients leukocytes</article-title><source>BMC Genomics</source><year>2013</year><volume>14</volume><fpage>478</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-14-478</pub-id><?supplied-pmid 23865419?><pub-id pub-id-type="pmid">23865419</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potashkin</surname><given-names>JA</given-names></name><name><surname>Santiago</surname><given-names>JA</given-names></name><name><surname>Ravina</surname><given-names>BM</given-names></name><name><surname>Watts</surname><given-names>A</given-names></name><name><surname>Leontovich</surname><given-names>AA</given-names></name></person-group><article-title>Biosignatures for Parkinson&#x02019;s disease and atypical parkinsonian disorders patients</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>8</issue><fpage>e43595</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0043595</pub-id><?supplied-pmid 22952715?><pub-id pub-id-type="pmid">22952715</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>JA</given-names></name><name><surname>Scherzer</surname><given-names>CR</given-names></name><name><surname>Harvard Biomarker</surname><given-names>S</given-names></name><name><surname>Potashkin</surname><given-names>JA</given-names></name></person-group><article-title>Specific splice variants are associated with Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2013</year><volume>28</volume><issue>12</issue><fpage>1724</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1002/mds.25635</pub-id><?supplied-pmid 24108702?><pub-id pub-id-type="pmid">24108702</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soreq</surname><given-names>L</given-names></name><name><surname>Guffanti</surname><given-names>A</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Simchovitz</surname><given-names>A</given-names></name><name><surname>Israel</surname><given-names>Z</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Soreq</surname><given-names>H</given-names></name></person-group><article-title>Long non-coding RNA and alternative splicing modulations in Parkinson&#x02019;s leukocytes identified by RNA sequencing</article-title><source>PLoS Comput Biol</source><year>2014</year><volume>10</volume><issue>3</issue><fpage>e1003517</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003517</pub-id><?supplied-pmid 24651478?><pub-id pub-id-type="pmid">24651478</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soreq</surname><given-names>L</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Bronstein</surname><given-names>M</given-names></name><name><surname>Greenberg</surname><given-names>DS</given-names></name><name><surname>Israel</surname><given-names>Z</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Soreq</surname><given-names>H</given-names></name></person-group><article-title>Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes</article-title><source>Front Mol Neurosci</source><year>2013</year><volume>6</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2013.00010</pub-id><?supplied-pmid 23717260?><pub-id pub-id-type="pmid">23717260</pub-id></element-citation></ref></ref-list></back></article>